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ABSTRACT
ASSESSING THE ROLE OF ARSENIC EXPOSURE AND MIRNA-186 IN SKIN
TUMORIGENESIS AND CHROMOSOMAL INSTABILITY
Angeliki Lykoudi
December 8, 2020

Chronic arsenic exposure through drinking water is a global health issue, affecting
more than 200 million people. Arsenic is a group I human carcinogen and causes
chromosomal instability (CIN). Arsenic exposure is the second most cause of skin
cancer after UV radiation. MiR-186 is overexpressed in arsenic-induced squamous cell
carcinoma relative to premalignant hyperkeratosis. Predicted targets of miR-186 are cell
cycle regulators. Thus, we hypothesize that miR-186 overexpression drives malignant
transformation of HaCaT cells by induction of CIN. Stable clones of HaCaT transfected
with pEP-miR-186 expression vector or empty vector were maintained under puromycin
selection were exposed to 0 or 100 nM NaAsO2 and cultured for 29 weeks. HaCaT
overexpressing miR-186 and exposed to NaAsO2 showed growth ability in agar at 12
weeks and increased CIN in contrast to unexposed vector control cells. These cells also
undergo epithelial to mesenchymal transition and form colonies in agar at 29 weeks.
These results suggest that miR-186 overexpression exacerbates the arsenite-induced
CIN and potentially is associated with accelerated skin carcinogenesis.
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CHAPTER 1: INTRODUCTION

1.1 Arsenic: An ambiguous and ubiquitous toxic metalloid
Heavy metals are ubiquitous in the environment and heavy metal-induced
environmental pollution is a global health hazard. Arsenic is a prevalent natural pollutant
and the 20th most common element in the earth’s crust (IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans., 2012). It is ranked first on the Agency for
Toxic Substances and Disease Registry (ATSDR) Substance Priority List for more than
20 years (ATSDR, 2017). Arsenic is a toxic metalloid and acknowledged carcinogen. In
1973, arsenic was classified as a group I human carcinogen by the International Agency
for Research on Cancer (IARC) [2]. Arsenic is also clastogenic and it causes
chromosomal instability (CIN) both in vitro and in vivo [3]. CIN is a hallmark of
carcinogenesis, and it is associated with poor prognosis, metastasis, and therapeutic
resistance [4]. The molecular mechanism by which arsenic induces CIN-mediated
carcinogenesis is yet to be delineated [5]. Arsenic has also an atherogenic potential
according to epidemiologic studies that have shown an association between elevated
arsenic levels in drinking water and an increased risk of atherosclerosis and
cardiovascular diseases [6] [7]. It is also reported that sodium arsenate induces
developmental malformations in a variety of experimental animals after subjecting
mothers to administration of teratogenic levels of arsenate [8].
Arsenic has been used since ancient times, both as a poison and a medicine. It is a
component of Chinese, Tibetan, Vietnamese, and Indian traditional medicines [9].
Arsenicals also are still used to treat some tropical diseases [9]. It is tasteless, colorless,
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and odorless, characteristics making arsenic a powerful poison throughout history. On
the other hand, potassium bicarbonate-based arsenic solutions were widely used to treat
asthma, convulsions, and psoriasis [10] [11]. Organic arsenic preparations such as
melarsoprol are widely used for the treatment of African trypanosomiasis [12]. Arsenic
was also approved by Food and Drug Administration (FDA) in 2001 for the treatment of
acute promyelocytic leukemia (APL) [13]. Trisenox is indicated for induction of remission
in patients with APL who are refractory to, or have relapsed from, retinoic acid
chemotherapy or have t(15;17) chromosomal translocation [13]. Moreover, arsenic
trioxide when used in combination with cisplatin (PDD) or doxorubicin (ADM) on
hepatocellular carcinoma, improved therapeutic effectiveness, and surmounted drug
resistance [14]. Also, it has been shown that cisplatin treatment alone, induces
xeroderma pigmentosum group C (XPC) expression [15]. XPC plays a role in the global
genomic nucleotide excision repair pathway, which detects and eliminates bulky adduct
DNA damage in the entire genome [16]. The latter could suggest that the cisplatinresistant cells are due to cisplatin-induced XPC expression [17]. However, cotreatment
of cisplatin-resistant ovarian carcinoma cells with arsenic suppressed the cisplatininduced XPC expression, thereby sensitizing wild-type p53-expressing cells to cisplatin
and increasing cellular and DNA platinum accumulation [18].
So, there is a paradox about arsenic, since it is a well-established toxicant and
carcinogen, but it is also used in medical applications, and specifically as a treatment for
APL. However, carcinogenicity is observed in patients who received arsenic treatment,
and its use has declined over the years. Thus, more investigation on arsenic’s
mechanisms of toxicity is crucial for delineating its toxic effects and its usage as a
cancer chemotherapeutic agent.
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1.2 Arsenic distribution and contamination of drinking water
Environmental arsenic contamination can be from natural or industrial sources, such
as arsenic-based pesticides, wood preservatives, feed additives, chemical warfare, and
industrial waste [19]. Ingestion is the primary source of exposure, and the main source is
drinking water. The World Health Organization (WHO) and the Environmental Protection
Agency (US EPA) have set the maximum contaminant level (MCL) at 10 ppb (μg/L) (in
2008). However, it is estimated that more than 200 million people consume water
contaminated with arsenic above the recommended limit [20]. Exposure to arsenic levels
that exceed the MCL for more than six months, leads to arsenicosis [21]. Also, in a study
performed in Inner Mongolia, China, it was shown that skin lesions improved after
drinking low arsenic-containing water for 1 year [21]. However, a 5-year follow-up
showed no more improvement of skin lesions [22]. Countries of South Asia and the
Americas, including Bangladesh, India (West Bengal), Taiwan, China and Argentina,
Mexico, Bolivia, Chile respectively, are highly affected by arsenic poisoning through
consumption of contaminated drinking water [23]. Specifically, more than 70 million
people in the Ganges River delta, spanning Bangladesh and West Bengal in India,
consume very high levels of arsenic via their drinking water, ranging from 40 μg/L to 2
mg/L [24] [25]. Also, in central and western China, ground and surface water contain
arsenic levels as high as 969 μg/L and arsenic metabolites were detected in residents’
urine samples [26] [27]. Arsenicosis and high risk for a wide range of chronic arsenic
exposure-associated health complications are observed in the populations mentioned
above [28] [29]. Most commonly, skin manifestations occur, for example, Blackfoot
disease is reported frequently [30]. The latter is a dry gangrene resulting from ischemic
changes in the toes accompanied by ulcers [30]. Arsenic contamination is also a
prevalent issue in the United States, since the EPA limits arsenic in public water
supplies, but not in private wells. Approximately, 15 % of the total population rely on
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domestic wells as a main water source [31] [32]. Thus, it is estimated that 2.9 million
people are at high risk due to contaminated (more than 10 ppb) private well water
consumption in the United States [33].
The most common route of arsenic exposure is through ingestion of naturally
contaminated food and water. An accurate measurement of the absorbed dose of
arsenic in tissues, is challenging, because of variation among individuals, like gender,
individual genetics, interactions with specific agents and occupational exposures [34].
The average blood arsenic level in people exposed to high levels of arsenic in their
drinking water for approximately 18 years, has been reported to be 100 nM and is
referred to as “physiologically relevant” [35] (see 2.1.1.).

1.3 Absorption, Distribution, Metabolism and Excretion (ADME) profile of arsenic
The main route of arsenic exposure is through ingestion and both pentavalent and
trivalent soluble arsenic compounds are absorbed from the gastrointestinal tract (GI
tract). Also, absorption of arsenic in inhaled airborne particles is dependent on the
solubility and size of the particles. The main site of arsenic metabolism is the liver, and
methylation is critical for arsenic metabolism. Frederick Challenger was the first to
suggest arsenic methylation as a major metabolic pathway [36]. Arsenic metabolism is
characterized by two main types of reactions: 1) reduction reactions of pentavalent to
trivalent arsenic by arsenate reductase and glutathione (GSH) [37]. 2) oxidative
methylation reactions in which trivalent forms of arsenic are sequentially methylated to
form mono-, di- and trimethylated products by arsenite (III) methyltransferase (AS3MT),
using S-adenosyl methionine (SAM) as the methyl donor [38] (Figure 1).
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Figure 1: The biotransformation pathway of inorganic arsenic in the human body [39]
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Methylation of inorganic arsenic facilitates the excretion of arsenic from the body
because the products MMAIII (monomethylarsonous acid), DMAIII (dimethylarsinic acid)
and DMAV (dimethylarsenic acid) are readily excreted in urine [40].
Moreover, Frederick Challenger and his colleagues described the arsenic
methylation pathway, however, alternative schemes for arsenic methylation including
glutathione-or protein-conjugated intermediates have been also suggested [41].
Specifically, it has been proposed that trivalent arsenic persists during methylation
reactions and that oxidation to pentavalent arsenic occurs after methylation [41] [42]. In
this alternative pathway, the arsenic-glutathione complexes are the major substrates for
arsenite (III) methyltransferase (AS3MT) and inorganic arsenic triglutathione (iAsIII (GS)3)
is produced and methylated to form, MMAIII(GS)2 and DMAIII(GS).
Methylation of arsenic is also considered to be a bioactivation and detoxification
pathway depending on the condition of arsenic exposure and its levels. Bioactivation
process is suggested to occur in case of long-term arsenic exposure, but in cases of
acute exposures, it may be a detoxification pathway [41]. All arsenic metabolites are
toxic to different extents. Reports have shown that MMAIII and DMAIII are more cytotoxic
and genotoxic than arsenite [43] [44]. Also, it has been found that MMAIII and DMAIII bind
differentially with zinc finger peptides and proteins [45] and they can inhibit the activities
of many enzymes in human hepatocytes, epidermal keratocytes and bronchial epithelial
cells respectively [41] [44].So, the products of arsenic metabolism exert toxic effects and
they are not just by-products.
Studies in humans suggest the existence of various AS3MT polymorphisms among
individuals which affect its activity [46]. Also, ingested organoarsenicals such as, MMAV
DMAV and arsenobetaine are much less extensively metabolized and more rapidly
eliminated in urine that inorganic arsenic in both experimental animals and humans [47].
Finally, some studies have also indicated that the arsenic methylating capacity varies
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depending on the tissue and the highest amount of arsenic methylating activity is in the
cytosol of testes, followed by kidney, liver, and lungs [48] [49]. So, arsenic retention and
tissue distribution depend on the bioconversion to methylated metabolites and
determines its toxic and carcinogenic potential [50].
The distribution of the different arsenic species depends on the animal or plant
species to which arsenic is administered and the different types of cells within the same
organism [41]. Rodent models are used for most of the toxicological studies of arsenic
effects. However, the ADME profile of arsenic differs significantly between rodents and
humans. Specifically, in rodents, during oxidative methylation, DMAV can be converted
into trimethylarsine oxide (TMAOV) [41]. Strain specific differences have also been
observed in rodents’ arsenic metabolism. For example, C57BL/6J mice are more
susceptible to oxidative hepatic injury compared with 129X1/SvJ mice after acute
arsenic exposure [51]. So, species and strain metabolic differences should be
considered during the experimental design, and data extrapolation to humans.

1.4 Acute and chronic arsenic poisoning
Arsenic toxicity depends on its dose and duration of exposure. Most cases of acute
arsenic poisoning occur from accidental ingestion of insecticides or pesticides and less
commonly from attempted suicide [52]. The symptoms of acute poisoning include,
abdominal pain, toxic cardiomyopathy, skin rash, hematological abnormalities, peripheral
neuropathy, and seizures [53] [54]. Usually, small amounts (less than 5 mg) cause
vomiting, dehydration, hypotension, and diarrhea but resolve after 12 hours without
treatment [52]. However, ingestion of large arsenic amounts requires treatment, such as
chelation therapy, gastric lavage, or administration of intravenous fluids. The lethal dose
of arsenic in acute poisoning ranges from 100 mg to 300 mg [55] or 0.6 mg/kg/day [52].
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So, depending on the quantity consumed, death can occur within 24 hours to four days.
For example, a study showed that a 23-year-old male who voluntarily took 300 mg of
arsenic daily, survived only 8 days [53]. For the acute arsenic poisoning diagnosis, a
twenty-four-hour urine test is more reliable than a blood test because arsenic is cleared
from the blood within 24 hours. Detection of urinary arsenic levels higher than 50 μg/L
are indicative of acute arsenic toxicity (Agency for Toxic Substances and Disease
Registry) [56].
Chronic exposure to arsenic results in multisystem disease and the most serious
health complications are cardiovascular disease and cancer [57] [52]. Chronic arsenic
poisoning causes dermatological changes, such as skin lesions (hyperkeratosis) and
changes in skin pigmentation [52]. Gastrointestinal complications also occur, including
diarrhea and vomiting. Also, chronic arsenic exposure increases the risk for
cardiovascular, neurodegenerative, and malignant diseases [52]. Long-term toxicity is
frequently observed in workers who are exposed to low levels chronically though their
occupation. Arsenite readily binds thiol or sulfhydryl groups in tissue proteins of the liver,
lungs, kidney, and skin [52], thus these tissues are the most affected organs of arsenic
toxicity. Specifically, keratin-rich tissues (skin, hair, and nails) have high content of
cysteine residues and arsenic accumulates in keratinocytes due to its reactivity with
cysteine thiol groups [58] [59]. So, arsenic levels analysis in hair and nails are useful
indicators for evaluating the time of arsenic exposure [60]. In individuals who have no
known arsenic exposure, the concentration of arsenic in hair and nails ranged from 0.02
to 0.2 mg/kg [61] [62]. In contrast, areas of West Bengal with arsenic concentration more
than 50 μg/L in drinking water, the arsenic level in hair ranged from 3 to 10 mg/kg [63].
Unfortunately, there is no effective treatment, although chelation therapy can be used
occasionally, to mitigate the toxic effects [64].
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Thus, arsenic can cause multisystem diseases and both the dose and duration of
exposure are critical for either the chronic or acute toxicity outcome. Also, different
tissues and organs are affected depending on chronic or acute exposure, and diagnosis
and treatment differ, respectively.

1.5 Arsenic and disease
Epidemiological evidence has linked chronic arsenic exposure with several severe
health conditions, including, cardiovascular disease, diabetes, pulmonary disease,
neurotoxicity, pregnancy complications, teratogenicity, developmental effects, and
cancers [65]. There is large amount of epidemiological data showing arsenic as a
common cause of disease [66]. One large study followed more than 165,000 individuals
from 17 municipalities in the Viterbo region of Italy for 20 years, showed that those
consuming groundwater with arsenic levels higher than 20 μg/L, had an 83% increased
risk of lung cancer and heart disease [66] [67]. Also, individuals consuming water with
levels higher than the US EPA maximum contaminant limit of 10 μg/L, had a 47%
increase in risk for chronic obstructive pulmonary disease (COPD) [66] [67]. A smaller
study in US that followed 3575 Americans between 1989 and 2008, showed that those
exposed to levels exceeding 61 μg/L, were 65% more likely to have cardiovascular
disease and 71% more likely to have coronary artery disease [68]. Another study in
Bangladesh showed that the mortality rate for cardiovascular disease was 214.3 per
100,000 person years in people drinking water containing <12 μg/L arsenic, compared
with 271.1 per 100,000 person years in people drinking water with ≥ 12.0 μg/L arsenic
[57]. There is a dose-response relation between exposure to arsenic in well water and
mortality from heart diseases as well as a significant synergistic interaction between
arsenic exposure and cigarette smoking in mortality from ischemic heart disease [57].
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To investigate the potential for in utero arsenic exposure to accelerate the onset of
cardiovascular disease, pregnant ApoE-knockout mice (ApoE-/-) were exposed to
arsenic in their drinking water [69]. Exposure of pregnant dams to arsenic exacerbates
atherosclerotic lesion formation in the offspring in ApoE-/- mice [69]. Early post-natal
exposure to 49 ppm arsenic for 7 weeks through drinking water increased the
atherosclerotic lesion formation by 3- to 5-fold in the aortic valve and the aortic arch [70].
Further exposure of ApoE-/- mice to 1, 4.9 and 40 ppm of arsenic for 13 weeks
increased the lesion formation and macrophage accumulation in a dose-dependent
manner [70]. Also, when mice were exposed for 21 weeks and then withdrawal of
arsenic for 12 weeks followed, decreased lesion formation was observed compared with
mice continuously exposed to arsenic [70]. Expression of pro-inflammatory chemokines
and cytokines as well as markers of oxidative stress were significantly increased in
lesions of arsenic-exposed ApoE-/- mice [70]. It was also shown that methylated
arsenicals are proatherogenic and that arsenic (3) methyltransferase (As3MT) is
required for arsenic to induce reactive oxygen species and promote atherosclerosis [71].
Methylated arsenicals can also cause changes in plaque components toward a more
unstable, rupture-prone phenotype [71].
In utero or childhood exposure to arsenic is also strongly associated with severe
diseases. Animal experiments have shown that arsenic is a transplacental carcinogen in
mice and transplacental exposure leads to tumor formation in offspring [72]. Strong
evidence of arsenic toxicity due to early life exposure comes from Chile. Specifically, in
1958, a new city water supply was installed in the city of Antofagasta in northern Chile
[73]. This water supply was using water from the Toconce and Holajar rivers, which
contained 800 and 1,300 μg/L of arsenic, respectively [73]. The exposure stopped in
1970 by an arsenic-removal plant and the arsenic concentration dropped to 110 μg/L for
about 10 years and reduced further since then [73]. From 1958 to 1970, more than
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125,000 residents were exposed to high levels of arsenic through their drinking water
[73]. Studies on mortality among adults 30-49 years of age showed increased mortality
due to lung cancer, bronchiectasis, myocardial infraction, and kidney cancer among
people born during the high-exposure period [74] [75] [76]. Also, another study on
investigation of all causes of death in young adults following early-life exposure in
drinking water to approximately 870 μg/L of arsenic in Antofagasta, showed increases in
mortality in young adults from liver, larynx cancer and chronic renal failure [73].
Additionally, two infants who were not related to each other from Antofagasta died from
myocardial infraction in 1973 [77]. The autopsies showed that the two infants had
arteriosclerosis and arsenic tests showed traces of arsenic in their hair and tissues [77].
Pathologic analysis showed no demonstrable etiologic evidence in the vascular lesions,
so the connection with arsenic, as in Blackfoot disease, should be considered [77].
A cohort study in Bangladesh revealed a dose-dependent increase in lower
respiratory tract infection (LRTI) in relation to maternal arsenic exposure [78].
Specifically, the study included 1,552 live-born infants of women in Matlab, Bangladesh.
Inorganic arsenic in maternal urine samples was measured [78]. After birth, information
on symptoms of LRTI was collected monthly. The results of the monthly check showed
that the estimated risk of LRTI increased by 69% in the participants whose mothers had
urinary arsenic concentration ranging from 262 to 977 μg/L, compared with offspring of
mothers whose exposure was less than 39 μg/L [78].
Chronic arsenic exposure via drinking water with arsenic concentrations as low as
10-50 μg/L can also cause peripheral neuropathy [79]. The impairment is observed
mainly in sensory fibers and less frequently in motor fibers [80]. Sural nerve biopsies
showed a reduction in both myelinated and unmyelinated fibers as well as axonal
degeneration of peripheral nerves because of chronic arsenic exposure [81]. Arsenicinduced peripheral neuropathy may recover in the long term; however, CNS impairments
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are less likely to recover [79]. It has been shown that arsenic trioxide significantly
decreased the activity of serum acetylcholinesterase in a dose-dependent manner [82].
The decreased acetylcholinesterase activity caused cholinergic crisis, which is probably
associated with peripheral neuropathy or CNS damage [82] [83]. The latter is the most
possible mechanism of arsenic-induced neurotoxicity [83].
Arsenic induces neural tube defects (NTDs) when given to animal models during
organogenesis [84]. A study from India showed a national NTDs rate of 4.4/1000[84].
With a birth cohort of approximately 26 million livebirths in India, this translates to
114,000 cases of NTDs per year [84]. Also, marked variations were observed between
regions in China, where the prevalence of NTDs in the Northern Regions was 4.5/1000
births, compared to 1.1/1000 in the Southern Regions [84] [85]. Due to the high rates of
NTDs in the Northern Regions, the health authorities took active measures by promoting
periconceptional folic acid supplementation [85]. Also, environmental factors that
contribute to high incidence of NTDs in China and India, should be considered and if
found, these factors should be reduced [85]. In the search for environmental causes for
NTDs, exposure to arsenic has been suggested as a risk factor [84] [86]. The Times of
India has reported that ~19% of Indians consume water with lethal levels of arsenic [84].
Also, most of the Chinese and Indian populations rely of rice as a dietary sample and
rice is a major source of arsenic exposure [84]. Rice is not very efficient in absorbing
arsenic from soil and it can absorb up to 10 times more arsenic than other crops [87].
Several studies have showed the association of environmental exposure to arsenic with
high incidence of NTDs. For example, analysis of gene expression in the neural tube of
arsenic-exposed embryos indicated that there was a significant dysregulation in a group
of genes directly involved in the mitochondrial process of energy production during
organogenesis [86]. A study from Bangladesh also showed that maternal consumption of
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high levels of arsenic via drinking water and rice, reduced the efficacy of folic acid in the
prevention of NTDs [84] [88].
Thus, arsenic exposure affects many organs and systems in a dose-dependent
manner and chronic arsenic exposure should be considered as a cause of many
commonly occurring severe diseases. Regulating arsenic levels in drinking water and
food and assessing the risk of exposure in areas that arsenic occurs in levels that
exceed 10 μg/L, would be crucial for disease prevention and control.

1.6 Arsenic-induced cancers
Arsenic causes several cancers, such as lung, bladder, kidney, liver and
nonmelanoma skin cancer [2]. Arsenic is classified as a group I human carcinogen by
the International Agency of Research on Cancer (IARC) since 1980 [89]. The latter
means that there is sufficient evidence of carcinogenicity to humans [90]. Despite
evidence in humans, animal models fail to replicate these observations. The lack of an
animal model has made it difficult to determine the exact mode(s) of action underlying
arsenic-induced carcinogenicity and these mechanisms of actions are yet to be
delineated [90].
Arsenic is a unique carcinogen because there is sufficient evidence of carcinogenic
risk by both inhalation and ingestion [89]. In a detailed study spanning a 7-year period, it
was shown that several patients had premature death due to cancer and had serious
arsenic skin lesions prior to that [89]. Data from Taiwan indicate that there is increased
risk of internal cancers form arsenic exposure through drinking water [89]. Specifically, in
a study of 8102 residents from an arsenic endemic area in Northeastern Taiwan, the
association between ingested arsenic and risk of cancers of urinary organs was positive
[91]. Additionally, a US study showed that there was an increased risk of bladder cancer
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in smokers that were exposed to arsenic in drinking water near 200 μg/L compared with
smokers exposed to lower arsenic levels [92].
Another study in Chile showed a positive correlation between ingestion of inorganic
arsenic and lung cancer [89] [93]. It was also shown that cigarette smoking plus
ingestion of arsenic had a synergistic effect for the development of lung cancer [93]. A
significant dose-response relationship between arsenic concentration in water and
incidence of lung and bladder cancers has been shown for both men and women [94].
Interestingly, the increased risk of lung cancer associated with arsenic is suggested to
be cancer subtype specific [90]. For instance, lung squamous cell carcinoma (SCC)
incidence had decreased worldwide and is associated with cigarette smoking. However,
in Bangladesh, no decline in lung SCC cases in non-smokers is observed and lung SCC
is the predominant histological subtype in areas with arsenic concentration above 100
μg/L [95].
A crucial relationship between arsenic exposure and skin cancer has been observed
[89]. It has been reported that arsenite can play a synergistic role in UV-induced skin
cancers [89]. Skin cancer in patients consuming arsenic-based medications was first
reported by Sir Jonathan Hutchinson in 1887 [96]. Bowen’s disease (intraepithelial
carcinoma or carcinoma in situ), basal cell carcinoma (BCC) and squamous cell
carcinoma (SCC) are the most common malignancies found in patients with chronic
exposure to arsenic [90]. Merkel cell carcinoma, a rare and aggressive cutaneous
neoplasm, has been also reported at a lower frequency [97].
So, chronic exposure to arsenic can not only cause non-malignant diseases (see
1.5) but also several cancers, affecting mainly the skin, lung, and urinary bladder. The
focus of this thesis is on arsenic-induced skin cancer since it is the most prevalent
cancer caused by arsenic.
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1.7 Arsenic-induced skin cancer
The second most common cause of skin cancer is chronic arsenic exposure [98].
Arsenic is a leading cause of skin cancer in areas where people are exposed to high
levels of arsenic in their drinking water and food [98]. An increased frequency of skin
cancer following treatment with Fowler’s solution (1% potassium arsenite) for various
hematological disorders was first observed in 1982 [99]. Arsenic-induced skin toxicity
symptoms first manifest as changes in the skin pigmentation including raindrop-shaped
lesions and diffuse dark brown lesions cancer [100]. The latter are frequently followed by
arsenical keratosis in the palms, soles, and trunk, and even by cutaneous malignancies
[98] [101]. These lesions are considered a diagnostic criterion of arsenicosis [90].
Chronic arsenic exposure is associated with different types of skin cancer,
progressing from premalignant hyperkeratosis (HK) to Bowen’s disease, BCC and SCC
(see 1.6). Arsenic-induced skin cancer has a different pattern of pathology and
progression to malignancy compared to sunlight-induced skin cancer [100]. The
premalignant lesions for both arsenic-induced BCC and SCC are arsenic hyperkeratosis,
whereas the premalignant lesions for sunlight-induced SCC are actinic keratoses [100].
Also, sunlight causes BCC, SCC, and malignant melanoma, while arsenic exposure
does not cause malignant melanoma [100]. Specifically, keratosis in areas of the body
that are not exposed to the sun is the most distinguishing cutaneous manifestation of
arsenic-induced skin lesions [102]. Dyplasia in the keratotic lesions is an intermediate
stage between premalignancy and malignancy and are immediate predecessors to
Bowen’s disease and SCC [103]. The most commonly occurring malignant lesions in
arsenicosis are Bowen’s disease and superficial BCC [102]. Specifically, BCC is not
invasive while SCC can be metastatic cancer, which tends to progress in later stages of
arsenic exposure [102]. Arsenic-induced Bowen’s disease can appear 10 years after
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arsenic exposure, whereas BCC and SCC can have a latency period of 20 or 30 years
[104].
Exposure of normal human epidermal keratinocytes to varying noncytotoxic
concentrations of inorganic arsenic causes gene expression changes in pathways
involved in oxidative stress and proliferation as well as increased transcriptional levels of
keratinocyte growth factors [105]. Also, arsenic toxicity can be potentiated by other
environmental carcinogens. In vitro studies combining arsenic and UV showed
significant oxidative damage in arsenic-treated cells compared to controls [106]. For
instance, arsenic-exposed people with a history of smoking, may be more prone to
develop skin lesions than nonsmokers [107]. Additionally, arsenic acts as a
cocarcinogen with UV light in a synergistic mode of action [107]. Models using UV
exposure of mice with concomitant drinking water arsenic revealed rapid skin tumor
formation, larger tumor size and a greater percentage of invasive SCCs than control
mice [108].
1.8 Modes of action in arsenic-induced carcinogenesis
The mechanisms of arsenic-induced carcinogenesis are not completely elucidated
and there are several proposed mode of actions including inhibition of DNA repair,
altered epigenetics (DNA methylation, miRNA expression), co-mutagenicity, oxidative
stress and chromosomal instability (numerical and structural chromosomal
abnormalities). [109].
Many studies have described arsenic’s ability to cause oxidative and nitrosative
stress via the production of reactive oxygen species (ROS) and reactive nitrogen
species (RNS) [98] [110]. Arsenic-induced genotoxicity in Chinese hamster ovary cells
and epidermal keratinocytes showed the presence of hydroxyl and hydrogen peroxide
ROS and confirmed the significance of ROS and the reduction of intracellular thiols,
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particularly glutathione, in the toxicity of arsenic [111]. Also, another study showed that
when arsenic-treated human-hamster hybrid cells were compared to mitochondriadepleted controls, the latter exhibited the necessity for mitochondria in arsenic-mediated
ROS production [98] [112]. This suggests that mitochondrial damage is required for
arsenic-induced DNA damage to occur [112]. Also, the human neutrophil cytochrome b
light chain (CYBA) protein, which is a critical subunit of NADPHO (nicotinamide adenine
dinucleotide phosphate oxidase) complex, was upregulated by arsenic exposure in
vascular smooth muscle cells [113]. Arsenic exposure contributes further to oxidative
stress by stimulating the translocation of Ras-related C3 botulinum toxin substrate 1
protein (Rac1) and thus activating NADPHO [114]. Monomethylarsonous acid (MMAsIII)
also readily binds the thiol moiety of nitric oxide synthase (NOS), which inhibits NOS
function and thus reduces the availability of NO [115]. Additionally, chronic arsenic
exposure has been associated with systemic nitric oxide (NO) depletion and arsenicinduced dysregulation of NO metabolism is implicated in high frequency of
atherosclerosis and peripheral vascular disease to individuals chronically exposed to
high levels of arsenic [116] [98]. These findings show that arsenic induces oxidative
stress through various mechanisms.
Arsenic causes genotoxicity and it is responsible for disrupting chromosomes and
DNA strands [98]. Arsenic-induced genomic instability is multi-factorial and involves
molecular crosstalk across various cellular pathways [117]. Genomic instability can be
caused through DNA damage, aberrant DNA repair, telomere dysfunction, mitotic arrest,
and apoptosis [117]. Also, epigenetic dysregulation could contribute to genomic
instability such as altered promoter methylation and miRNA dysregulation [117]. One
study with 60 residents of West Bengal in India showed significantly increased incidence
of chromosomal aberrations and sister chromatid exchange in lymphocytes from DNA of
arsenic-exposed individuals [118]. Chronic arsenic exposure modulates DNA
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methylation, histone maintenance, mRNA, and miRNA expression [119]. Altered DNA
methylation has been related to arsenic’s ability to generate ROS and deplete methyl
group donors such as S-adenosylmethionine (SAM). Tri- and pentavalent arsenic
species receive methyl groups from SAM to form di- and monomethylated arsenic. So,
these methylated arsenics reduce the available pool of SAM and directly methylate DNA
in an abnormal manner [90] [98] [120]. Also, arsenic-treated prostate epithelial cells
showed a significant suppression of SAM levels occurred with decreased methionine
adenosyltransferase 2A (converts methionine to SAM) expression [120]. Cellular arsenic
adaptation is a dynamic process involving decreased SAM recycling and this disruption
in metabolism may have an impact on arsenic-induced oncogenesis [120]. Also, analysis
of bladder cancers from patients with high arsenic exposure showed a low rate of tumor
protein 53 (TP53) mutations present in patients who had used hair dyes, suggesting that
arsenic exposure did not promote mutagenesis in humans [121]. Arsenic exposure alone
is not sufficient to induce cancer in adult animals but arsenic acts as a co-carcinogen
and enhances tumorigenesis after exposure to other agents such as UV radiation [108]
[122]. TP53 mutation is known to be a driver for UV-induced squamous cell carcinoma
and arsenic-induced increase in sunlight-induced mutagenesis was shown in rodent
studies [108]. However, arsenic-induced skin tumors showed neither TP53 mutations nor
mutations associated with UV light exposure [123].
Moreover, arsenic impacts many cellular DNA repair mechanisms. Specifically, it
inhibits nucleotide excision, base excision repair, and mismatch repair pathways [124]
Poly (ADP-ribosyl)ation of nuclear proteins following DNA damage is catalyzed by poly
(ADP-ribose) polymerase 1 (PARP1) and it is required for the dissociation of nuclear
proteins so that base excision repair proteins can access the damaged site and repair
the DNA [125]. Long term exposure to low arsenic levels (0.1 μΜ) led to poly (ADPribosyl)ation of TP53 and PARP1 in HaCaT cells [126] [125]. It is known that after DNA
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damage induced by a genotoxic agent, activated TP53 induces expression of cyclin
dependent kinase inhibitor 1A (CDKN1A aka p21CIP1/WAF1), which then causes cell cycle
arrest allowing for damaged DNA to be repaired before cell cycle further progresses
(reviewed in [125]). However, studies showed decreased expression of CDKN1A mRNA
and protein after concomitant exposure to arsenic and another genotoxic agent. The
latter suggests the inactivation of TP53 function following its poly (ADP-ribosyl)ation
induced by arsenite [125] [126]. A study on the effect of arsenic and its metabolites on
base excision repair pathway in human A549 lung cancer cells showed that arsenite at
10 μM or greater significantly decreased the levels of DNA ligase IIIa (LIG3) [127].
Dimethylarsinic acid (DMAV) starting at 5 μΜ decreased human 8-oxoguanine DNA
glycosylase-1 (OGG1) activity [127]. Monomethylarsonic acid (MMAV) and arsenite also
decreased the X-ray cross complementing protein 1 (XRCC1) levels at 2.5 and 5 μΜ
respectively [127]. Additionally, low concentration of arsenite (10 nM) inhibited PARP1 in
HeLa cells and increased the number of DNA strand breaks by H2O2 [128]. Arsenite
targets the zinc finger motifs containing three or more cysteine residues in DNA repair
proteins, such as xeroderma pigmentosum group A (XPA) and PARP1 [129] [130], which
are essential DNA repair enzymes [117]. Thus, repair of oxidative DNA damage is
inhibited [125]. Also, inhibition of PARP1 activity by arsenite was shown in HaCaT cells
treated with UV light and this effect was diminished after adding zinc (II) ions [131] [125].
Arsenic displaces phosphate in ATP and covalently binds with sulfhydryl moieties of
DNA repair machinery enzyme [132]. Particularly, arsenite (> 5 μΜ) inhibits O6-methylguanine-DNA methyltransferase, and PARP-1 [132]. Also, polymorphisms of the DNA
repair pathway genes, such as the excision repair cross-complementation group 2
(ERCC2), tumor protein 53 (p53), apurinic/apyrimidinic endonuclease 1 (APE1), X-ray
repair cross complementing 3 (XRCC3) and Nijmegen breakage syndrome (NBS1) have
been associated with risk of development of arsenic-induced skin lesions [117]. Arsenic
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also promotes genomic instability by interfering with telomere function [117]. Many in
vitro and in vivo studies have shown that at low doses of arsenic, telomerase activity and
telomere length are maintained, while at higher doses, telomerase activity is decreased
with telomeric DNA attrition and apoptosis [117]. Arsenic can also induce some positive
regulators of telomerase and cell proliferation like heat shock proteins (such as Hsp90),
oncogenes (such as MYC proto-oncogene (c-myc)) and some growth factors (such as
epidermal growth factor (EGF)) and these could be mechanisms of arsenic-induced
alteration of telomerase activity [117]. Hence, the altered telomere states due to arsenic
exposure is thought to be a major reason for arsenic-induced senescence [117].
Moreover, the anaphase promoting complex/cyclosome (APC/C) which regulates
progression through mitosis and entry into G1 phase is known to be perturbed by
arsenic. Specifically, arsenic disrupts mitosis and delays transit through M phase in
SV40-transformed human skin fibroblasts [133]. Disruption of the APC/C by arsenite is
consistent with the observation of disruption of mitotic progression by arsenite [125]
[133]. Also, studies showed that mitotic arrest induced in A375 malignant melanoma
cells by arsenite is associated with the phosphorylation of the BUB1 mitotic checkpoint
serine/threonine kinase B (BUBR1) [134] [135]. Phosphorylation of BUBR1 occurs
during spindle checkpoint activation by mitotic disrupting agents [135]. Spindle
checkpoint activation by arsenite resulted in stabilization of cyclin B and securin, thus
inhibiting mitotic exit [134]. Arsenite also promoted activating Thr161 phosphorylation on
cyclin dependent kinase 1 (CDK1) and reduced inhibitory phosphorylation at Tyr15,
leading to increased CDK1 activity that maintains spindle checkpoint activation and
further inhibits exit from mitosis [136]. The transcription of signaling kinase genes
upstream of TP53 was also decreased in ovarian cells after arsenic exposure: ATM
serine/threonine kinase (ATM) was down two-fold; ATR serine/threonine kinase (ATR),
three-fold; and checkpoint kinase 1 (CHEK1). Thus, arsenite exposure downregulates
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transcription of many DNA damage signaling genes, possibly contributing to disrupted
DNA damage responses [125]. In summary, arsenic interferes with the DNA damage
response at multiple levels and disrupts cell cycle control mechanisms. Thus, arsenic is
a genotoxic agent with many deleterious effects and some of these mechanisms could
be implicated in genomic instability observed in arsenic-induced tumors [117].
There is also evidence that arsenic plays a role in the disruption of the innate and
cell-mediated immune responses [98]. Studies showed an association between lower
respiratory tract infections and diarrhea in individuals with a history of chronic arsenic
exposure [137]. Arsenic reduces the pulmonary antibacterial defenses mediated by
innate immune cells in rodents [98]. Also, arsenic-exposed mice exhibited greater
influenza virus infectivity because of inhibited T cell function, when compared to controls
[138]. Impaired immune responses were reported among patients treated with
therapeutic arsenic trioxide (ATO) since they were found to have a greater incidence of
herpes simplex and herpes zoster infection among multiple myeloma and colon cancer
patients treated with ATO [139]. Some mechanisms by which arsenic mediates
disruption of immune responses includes the unfolded protein response (UPR) [98].
Specifically, UPR is a homeostatic mechanism that is activated in response to an
increased number of unfolded or misfolded proteins present in the endoplasmic
reticulum (ER) lumen. Studies have shown that arsenic exposure upregulates sensors of
the UPR pathway in the epidermis of SKH-1 mice [98]. Treatment with antioxidants such
as N-acetylcysteine (NAC) decreased the arsenic-induced cutaneous inflammation of
these mice, providing evidence of the involvement of ROS in UPR activation [140]. So,
ER stress in arsenic toxicity could be a possible mechanism by which this metalloid
altered cellular differentiation leading to cutaneous inflammation [98]. Also, ATO
treatment disrupted murine macrophage function by simultaneously generating ROS and
activating the UPR pathway [98].
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Many of the adverse effects caused by arsenic are mediated by aberrant activation
of various signal transduction pathways. Arsenic directly binds sulfhydryl (SH) moieties,
and this interaction may occur in over 200 known human proteins [141]. Most pathways
affected by arsenic may lead to the activation of oncogenes, the inhibition of tumor
suppressors, and/or the upregulation of inflammatory pathways [98]. Arsenic activates
the canonical Hippo pathway that is responsible for cell survival and proliferation and
implicated in many malignancies [142]. Yes-associated protein (YAP) is a known
component of the Hippo signaling pathway and dephosphorylated, it acts as a
transcription factor in the regulation of epithelial cell proliferation [98]. A downstream
target of the dephosphorylated YAP is a downstream effector of Sonic hedgehog (Shh)
pathway, which has been implicated in arsenic-induced basal cell carcinoma [143].
Additionally, arsenic-mediated ROS have been found to promote nuclear factor kappalight-chain-enhancer (NFκB) mediated apoptosis [144]. Also, arsenic exposure induces
the overexpression of epidermal growth factor receptor (EGFR) [145]and increased level
of EGFR ligand mRNAs, specifically HB-EGF, which is upregulated in many colorectal,
cervical, breast and gastric cancers [146]. Furthermore, exposure to arsenite promotes
epithelial to mesenchymal transition (EMT) and angiogenesis by increasing signaling
through the β-catenin vascular endothelial growth factor pathway [88]. Arsenic also
activates the mineral dust induced gene (MDIG), also known as myc-induced nuclear
antigen 53 and nucleolar protein 62 by upregulating Jun-N-terminal protein kinase (JNK)
and signal transducer and activator of transcription 3 (STAT3) pathways [98]. MDIG is
an oncogene that has been linked to lung, breast, colon, gastric, renal, and esophageal
squamous cell carcinomas [147]. Hence, arsenic’s ability to perturb signal transduction
makes it an important carcinogen in many cancers.
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1.9 MicroRNAs (miRNAs): Biogenesis, processing, and regulation of translation
MicroRNAs are part of the epigenome and play a significant role in the regulation of
gene expression at the post-transcriptional level [148]. miRNAs are endogenous short
non-coding RNAs (containing ~22 nucleotides) and are transcribed by RNA polymerase
II as miRNA genes or in protein coding genes embedded in introns [149]. It is estimated
that miRNAs target more than 60 % of protein-coding regions and silence genes posttranscriptionally by guiding Argonaute (AGO) proteins to mRNA targets [150].
The biogenesis of the mature miRNA is a two-step process (Figure 2) [151] [152].
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Figure 2: miRNA biogenesis occurs in both the nucleus and the cytoplasm and the
regulation of their target mRNAs [150] [153].
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Initially, the pri-miRNA, which is the nascent miRNA transcript, is cleaved in the
nucleus by the microprocessor complex containing the double-stranded RNA-specific
ribonuclease Drosha, into pre-miRNA (~85 nucleotide pre-mRNA hairpin) (Figure 2)
[153]. The cleaved pre-miRNA is then transported from the nucleus to the cytoplasm by
exportin 5 where it is processed to ~21-25 nucleotide single-stranded mature miRNA by
a protein complex consisting of Dicer (a helicase with RNAse motif) and TRBP (HIV-1
TAR RNA binding protein) (Figure 2) [152] [154]. Dicer and TRBP recruit AGO2 and
other argonaute proteins to mediate the assembly of the RNA-induced silencing (RISC)
complex [152] [154]. RISC is a ribonucleoprotein complex that binds to one of the
miRNA strands and guides the miRNA to the target mRNA to regulate translation [153].
MiRNAs target cytosolic mRNAs by forming complementary base pairing, typically
with the 3’ untranslated regions (UTRs) of the target mRNAs within the RISC complex.
The complementary sequences in UTRs with which miRNAs bind, are known as seed
regions. The hybridization of miRNAs to seed regions leads to decreased translation,
deadenylation or degradation of the mRNA [155] [156]. In cases of perfect base pairing
of miRNAs with the seed regions of their target mRNA, the mRNA is degraded.
However, imperfect base pairing leads to repression of mRNA translation and restoration
of translation is possible when the repressor miRNA is degraded [157].
MiRNAs play a complex and crucial role in many biological processes (cell
proliferation, apoptosis, response to therapy, diseases, development) and can create
complex feedback regulatory loops in a cell [158] [159]. A single miRNA can target
hundreds of mRNAs and each mRNA can be targeted by multiple miRNAs in different
regions [159] [157]. MiRNAs also can bind to the 5’-UTR or the open reading frame
(ORF) regions, creating a complex network of interactions [159]. Some miRNAs may
also regulate gene families by targeting regions withing their genes [160]. For example, it
has been shown that many zinc finger genes (ZNFs) are regulated at the post-
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transcriptional level by miRNAs, which directly target their coding regions [160]. So,
there is a complex mechanism of miRNA/mRNA interplay, which should be considered
in studies of gene regulation and expression [160].

1.10 Role of miRNAs in carcinogenesis
Several studies have linked aberrant miRNA expression or dysregulated expression
of components of miRNA processing machinery (i.e. Dicer, Drosha, RISC complex) with
different cancers [161], [162] [163]. Studies have shown the association of dysregulated
miRNA expression with lung, cervical, oral, squamous cell carcinoma (SCC) [161],
breast, colon, prostate, and thyroid cancers [164]. MiRNA dysregulation can affect tumor
development, progression, and response to therapy (drug resistance) [165]. Specifically,
miRNAs dysregulation in cancer involves targeting of oncogenes and tumor
suppressors, resulting in changes in gene expression, stem cell biology, angiogenesis,
epithelial-mesenchymal-transition, and metastasis [165]. Thus, miRNAs can act either as
novel oncogenes by suppressing tumor suppressor genes, or as tumor suppressor
genes by suppressing oncogenes (Figure 3) [1] [166] [167].
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Figure 3: miRNAs may act as tumor suppressors and oncogenes
leading to carcinogenesis [1]
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For example, in Burkitt lymphoma cells, miRNA let-7a downregulates expression of
the proto oncogene MYC reverting the MYC-induced cell growth [168]. Studies have
also shown the regulation of MYC and RAS expression by let-7a microRNA family in
lung and colon cancers [169] [170]. Alternatively, overexpression of miR-504 decreases
TP53 expression levels, resulting in decreased TP53-mediated apoptosis, and cell cycle
arrest in response to stress [171]. Thus, the impact of miRNAs on carcinogenesis is
significant and miRNAs may function as potential biomarkers for prognosis, diagnosis,
and therapy [165] [158]. MiRNAs can also be dysregulated in response to environmental
stress. Several studies have shown that various arsenic concentrations and different
times of exposure can alter the miRNA expression profile in arsenic-induced cancers in
different cell lines both in vitro and in vivo [172] [173].

1.11 Dysregulated miRNAs in arsenic-induced cancers
Exposure to environmental chemicals has been associated with altered miRNA
expression profile and carcinogenesis [174]. For example, arsenic alters both the mRNA
and miRNA expression levels in arsenic-induced cancers and transformed cell lines
[173] [175].The impact of arsenic exposure on altered miRNA responses was first
reported in 2006, when it was shown that miRNA profiles are altered by folate deficiency
and arsenic exposure [174]. Also, there is evidence for the therapeutic potential of
arsenic in leukemia by regulating miRNAs as well as exploiting the synergistic effects of
miRNAs and arsenic trioxide (ATO) for leukemia chemotherapy [176] [177]. Specifically,
the combination of miRNA-15a/16-2 and ATO induced apoptosis in BCR-ABL positive
myelogenous leukemia cells (K562) and could be a potential treatment of chronic
myeloid leukemia [176]. Moreover, anti-miR-21 sensitizes leukemic K562 cells to arsenic
trioxide by inducing apoptosis [177]. Several reports have also shown that expression of
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let-7 miRNA family and miRNA-200 are altered in response to exposure to various
arsenic doses and arsenicals in several arsenic-induced tumors [165]. These studies
suggest that miRNA expression plays a crucial role in arsenic-induced carcinogenesis by
either promoting or inhibiting malignant transformation.

1.12 Dysregulated miRNAs in arsenic-induced skin cancers
Chronic exposure to arsenic has been linked to cancer development in different
organs and tissues. Skin is the major target for arsenic toxicity [178]. Arsenic-exposed
keratinocytes have been shown to exhibit differential miRNAs expression profile [179].
Specifically, exposure of human immortalized keratinocytes (HaCaT cells) to 500 nM
sodium arsenite for 4 weeks resulted in overexpression of miR-21, miR-200a, and miR141 [179]. MiR-21 and miR-200a have been reported to be associated with most human
tumors [179] [180] and miR-141 family is associated with epithelial-mesenchymal
transition (EMT) during malignant transformation and cancer progression [179]. Analysis
of human serum samples from individuals exposed to arsenic in West Bengal, India,
showed that miR-21 is overexpressed in exposed individuals compared with
nonexposed [175]. Also, in the arsenic exposed group, the levels of miR-21 are even
higher in individuals with skin lesions compared to individuals without skin lesions [175].
In vitro, when HaCaT cells were exposed to 0.05 ppm of sodium arsenite for 8 weeks,
miR-21 levels were upregulated [175]. Banerjee et al., 2017 also showed that PTEN
(phosphatase and tensin homolog) and PDCD4 (programmed cell death 4) levels, which
are tumor suppressor downstream targets of miR-21, were decreased with miR-21
overexpression. The latter findings suggest that miR-21 possibly contributes to arsenicinduced skin lesions in exposed individuals and transformation in HaCaT cells in vitro
[150]. Moreover, accumulating evidence has shown that let-7 miRNA family functions as
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tumor suppressors and regulate various biological processes, such as cell proliferation,
cell cycle, migration, and stem cell biology [181].
Overexpression of let-7c inhibits arsenite-induced acquisition of cancer stem cell like
properties and neoplastic transformation of HaCaT cells [182]. Exposure of HaCaT cells
to 1 μM arsenite for 15 weeks leads to neoplastic transformation and transformed
HaCaT cells had decreased levels of let-7 family miRNAs [182]. The levels of let-7c were
also decreased in a time-dependent manner in acute exposure experiments [182] [183].
Analysis of skin lesions from individuals chronically exposed to high levels of arsenic
(59-172 ppb) in their drinking water in West Bengal, India showed altered miRNA profile
[183]. Differential miRNA expression patterns were observed when comparing
expression in three premalignant HK (hyperkeratosis) lesions and six malignant lesions
(three squamous cell carcinoma (SCC) and three basal cell carcinoma (BCC)) [183].
This study [183] showed the differential expression of 35 miRNAs in arsenic-induced
premalignant and malignant lesions. Specifically, the differential expression was shown
in phenotypic and stage-related manner, for example, expression of miR-425-5p and
miR-433 were higher in both BCC and SCC relative to HK, which suggests that
upregulated levels of miR-425-5p and miR-433 are associated with progression from
premalignant to malignant lesions [183].
The studies described above show that miRNA dysregulation is one of the effects of
arsenic-induced toxicity and plays a vital role in the malignant transformation of human
keratinocytes. Since skin is the primary target organ of arsenic toxicity and there is
aberrant miRNA expression profile, studies that assess the effects of different miRNAs
throughout the transformation process are critical during the investigation of
mechanisms of arsenic-induced skin cancer.
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1.13 Association of miR-186 with carcinogenesis
MiR-186 may play a crucial role in various biological processes and may act as an
oncogenic or tumor-suppressor miRNA. The likely role of miR-186 in carcinogenesis has
been reported and dysregulated miR-186 levels can either promote or inhibit
tumorigenesis [184] [150]. MiR-186 was found to be highly upregulated in some cases of
squamous cell carcinoma induced by chronic arsenic exposure via drinking water,
relative to non-malignant hyperkeratosis [109] [183]. On the other hand, the inhibitory
effect of miR-186 has been demonstrated on melanoma cell growth, migration, and
invasion in vitro, exerting tumor suppressor function in human malignant melanoma cells
(CMM) [184]. Moreover, it has been shown that the level of pituitary tumor transforming
gene (PTTG1) (also known as securin) expression correlates with clinicopathological
features and patient survival in non-small cell lung cancer (NSCLC) and promotes
NSCLC cell invasion under miR-186 modulation [185]. Also, aberrant miR-186
expression occurs in metastatic melanoma [186] and metastatic pancreatic cancer [187].
Baffa et al. indicated that miR-186 was differentially expressed in paired primary and
metastatic cancers [188]. Leidinger et al. showed that miR-186 in combination with other
miRNAs was a biomarker that distinguished melanoma patients from healthy individuals
[189]. According to the studies mentioned above, there is strong evidence that miR-186
plays a significant role in carcinogenesis and is associated with either progression or
inhibition of cancer.

1.14 The role of miR-186 in carcinogenesis through regulation of cell cycle
Dysregulation of miR-186 is also involved in chromosomal instability, which is a
hallmark of carcinogenesis. The ambiguous role of miR-186 in carcinogenesis via
regulation of cell cycle has been reported. Downregulation of miR-186 promoted cell
cycle progression and proliferation in non-small cell lung cancer (NSCLC), resulting in
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adverse prognosis [185]. On the other hand, upregulated miR-186 targeted cyclin D1
(CCND1), and cyclin-dependent kinases 2 (CDK2) and 6 (CDK6), arresting cells in G1/S
checkpoint and inhibiting growth of lung cancer cells [185]. Also, it has been shown both
in vivo and in vitro, that miR-186 suppress protein phosphatase 1B (PPM1B). PPM1B is
a phosphatase that dephosphorylates cyclin-dependent kinases (CDKs) and
overexpression of PPM1B is reported to cause cell-growth arrest. Suppressed PPM1B
by miR-186 promotes G1/S cell cycle transition, driving cell cycle progression in bladder
cancer [190]. On the other hand, miR-186 also negatively regulated cell growth through
cell cycle arrest and apoptosis in malignant fibroblasts [191]. The reports mentioned
above, suggest a contradictory role of miR-186 in carcinogenesis via regulation of cell
cycle.

1.15 MiR-186 targets cell cycle proteins in arsenic-induced skin cancer
Preliminary results have shown that chronic arsenic exposure induces miR-186
expression [109]. Upregulated miR-186 suppresses securin, which is one of its targets
[185] [109]. Normally, securin binds to and inhibits a protease called separase, which,
when released, following securin degradation, cleaves cohesins that hold the sister
chromatids together, thus initiating anaphase [192]. Therefore, suppressed securin
levels, because of overexpression of miR-186, allows anaphase progression and
contributes to aneuploidy by promoting premature chromatid separation [109]. Securin’s
suppression facilitates progression from metaphase to anaphase but also contributes to
chromosomal instability, which is a defining characteristic of most human cancers [193].
Arsenic induces mitotic arrest associated with securin stabilization [134]. It has been
suggested that miR-186 overexpression in chronic arsenic exposure could mitigate
securin stabilization and contribute to escape from arsenic induced mitotic delay [109].
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Also, dysregulated securin could cause aberrant chromatid segregation, resulting in
aneuploidy and carcinogenesis [109] [5]. The latter suggests that miR-186 dysregulation
could be involved in chromosomal instability, which is a feature of carcinogenesis [5]
[193].
Bioinformatic analysis using the DIANA miRPath V3.0, has shown that miR-186 is
predicted to target mRNAs of proteins that regulate the cell cycle and are components of
the spindle assembly checkpoint (SAC) and anaphase promoting complex (APC),
including: budding uninhibited by benzimidazoles 1 (BUB1), cell division cycle 27,
(CDC27), and BUB1-related protein 1 (BUBR1) [194]. Ectopic expression of miR-186 in
HaCaT cells induces significant increase in chromosome number and in structural
chromosomal abnormalities [5]. The latter occurs because miR-186 targets and
suppresses BUB1, a mitotic checkpoint serine/threonine kinase, which plays a role in the
establishment of the mitotic spindle checkpoint and proper chromosome segregation.
Specifically, overexpression of miR-186 causes aneuploidy in HaCaT cells, which is
further increased with chronic arsenite exposure [5]. Overall, the studies described
above, suggest that miR-186 plays an essential role in arsenic-induced skin
carcinogenesis and contributes to chromosomal instability.

1.16 The biology of the spindle assembly checkpoint
The successful attachment of chromosomes, through its sister kinetochores, to
microtubules of the mitotic spindle, is crucial for error-free chromosome segregation
[195]. Genomic stability and proper chromatid separation are ensured by monitoring the
kinetochore-microtubules interactions and the spindle assembly checkpoint (SAC) [196].
The presence of unattached or improperly attached kinetochores, is the signal for SAC
activation, and it functions as a platform for the assembly of the mitotic checkpoint
complex (MCC). The MCC signals inhibition of the metaphase to anaphase transition (
Figure 4) [196].
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Figure 4: The molecular basis of spindle assembly checkpoint (SAC) signaling [196]
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The MCC consists of the highly conserved proteins: mitotic arrest deficient 2 like 1
(MAD2), BUBR1 and budding uninhibited by benzimidazoles 3 (BUB3) in association
with CDC20 [196]. CDC20 is a coactivator of the E3 ubiquitin ligase anaphase promoting
complex/ cyclosome (APC/C) [197]. Once MCC is activated, cell division cycle 20
(CDC20) is unable to activate the APC/C, preventing anaphase onset by inhibiting
securin degradation by the ubiquitin/protease system (
Figure 4) [196]. This way, sister-chromatid cohesion is maintained, and the cell cycle is
arrested. A single free kinetochore can activate the SAC transduction pathway and
sustain a mitotic arrest, because the inhibitory signal that comes from the unattached
kinetochore is further amplified within the cytoplasm [198]. The catalytic conformational
conversion of MAD2 causes the diffusion and amplification of the inhibitory signal [196].
The binary complex MAD1- “closed” MAD2 at unattached kinetochores, acts as a
scaffold for a continuous conversion of the cytosolic “open” MAD2 into “closed” MAD2.
The latter can bind CDC20 and inhibit APC/C activity [196] [199] [200]. A “closed”
MAD2-dependent CDC20 conformational change allows the binding of CDC20 with the
N-terminus of BUBR1 bound to BUB3, which in turn inhibits the APC/C activity and
anaphase onset (
Figure 4) [201]. When all kinetochores have aligned, the MCC disassembles and CDC20
is released [196] (
Figure 4). CDC20 activates the APC/C, leading to securin and cyclin B degradation.
APC/C catalyzes the poly-ubiquitinylation of securing and cyclin-B, leading to ubiquitinmediated proteolysis. Securin degradation leads to the activation of the protease
separase, which cleaves cohesins, leading to sister-chromatid separation [196] (
Figure 4). Cyclin B degradation decreases the cyclin-dependent kinase (CDK1) activity,
which results in mitotic exit [196]. Thus, by stabilizing securin and cyclin B, the SAC
prevents premature sister-chromatid separation in the presence of unattached
kinetochores, and maintains the mitotic state, respectively.
Some other components of SAC are the kinases BUB1, monopolar spindle 1
(MPS1), and aurora B, which are essential for proper checkpoint signaling [196]. BUB1
forms a constitutive complex with BUB3 and is required for kinetochore recruitment of
BUBR1, MAD1, and MAD2 [202]. BUB1 also inhibits APC/C via CDC20 phosphorylation
[203]. BUB1 phosphorylates members of the MCC and activates it, inhibiting APC/C
activation [196]. BUB1 binds to the kinetochore and delays mitosis in response to
spindle disruption, so BUB1 is critical to high fidelity chromosome segregation [184].
Loss of function mutations or absence of BUB1 results in chromosomal instability and
premature senescence. Deletions have been identified in some aneuploid tumor cell
lines and primary tumors [204]. Kinetochore targeting of MAD1 and MAD2 is also
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dependent on MPS1 which is essential for aurora B kinase activation [205]. Aurora B
recruits BUB1 and MAD2 to the kinetochore and has an important role in correcting
aberrant kinetochore-microtubule attachments by sensing and destabilizing improper
kinetochore-microtubule attachments, reducing aneuploidy [206] [207].

1.17 Spindle assembly checkpoint and aneuploidy in carcinogenesis
Disrupted mitosis results in chromosomal instability and aneuploidy which is a
common feature of human tumors and a contributory factor in tumorigenesis [208] [209].
The cell must ensure that each daughter cell only receives one copy of each
chromosome, in order to maintain the same karyotype in every cell. The latter is
regulated by SAC; thus, a compromised SAC will result in aneuploid cells, with either
extra or fewer chromosomes, a state that contributes to tumorigenesis [196]. An
impaired MCC is associated with an increase in aneuploid cells, however cells may still
be able to divide and survive [196]. The chromosome gain or loss is known as
chromosomal instability (CIN), a hallmark of carcinogenesis correlated with poor patient
prognosis [210].
Chronic SAC activation is frequently used in chemotherapy and is based on the use
of microtubule-targeting agents, which by disrupting microtubule dynamics, elicit a longterm SAC response that often results in mitotic cell death [196] [211]. However, some
cells can escape cell death and exit mitosis (mitotic slippage) [212]. The cell fate (either
mitotic slippage or mitotic cell death) is dependent on the efficiency of the apoptotic
machinery and the threshold of cyclin B degradation [213]. If the apoptotic machinery is
activated during the mitotic arrest, before cyclin B reaches a threshold of degradation,
then the cell dies [213]. On the other hand, if the threshold of cyclin B degradation is
reached before activation of apoptotic machinery, then mitotic exit occurs [213]. All the
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above show that a fine-tuning of SAC activity is essential for cell survival, since an
impaired SAC can favor tumorigenesis but the absence or chronic activation of SAC
results in apoptosis in normal and cancer cells [210].

1.18 HaCaT model of arsenic-induced skin carcinogenesis
HaCaT cells are a spontaneously immortalized human keratinocyte cell line that
maintains full epidermal differentiation capacity and was established in 1988 from adult
male human skin [214]. HaCaT cells have unlimited growth potential and express
differentiation-specific keratins (keratin-1 and 10) and other markers including involucrin
and filaggrin [214]. They do not have a tumorigenic phenotype in vitro and they are not
invasive in vivo [214]. HaCaT cells exhibit normal differentiation and provide a promising
tool for studying regulation of keratinization in human cells [214]. These cells were
initially hypodiploid with unique stable marker chromosomes indicating monoclonal origin
[214]. In passage 2, most cells were hypodiploid with an average of 44 chromosomes
resulting from full or partial monosomies of chromosomes involved in the formation of
marker chromosomes [214]. All metaphases had the XO sex chromosome constitution
(lacking the Y chromosome) and were partially monosomic for the short arm of
chromosomes 3, 9 and 4 [214]. In later passage, they were monosomic for the whole
chromosome 4 [214]. They were also trisomic for the long arm of chromosome 9 (i[9q])
[214]. Three individual marker chromosomes (M1: t(3q4q), M2: i[9q] and M3: del(4q28))
were present in 100% of the cells and indicated the clonal origin of this cell line [214].
The presence of these marker chromosomes could be used to validate the authenticity
of the cells and exclude cross-contamination with other human cell lines. At passage 5 a
hypotetraploid stem line evolved with a range of 72-88 chromosomes, including
duplication of the early marker chromosomes and the presence of a fourth marker
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chromosome M4:[4p18q] which replaced the M3: del(4q28) [214]. These cytogenetic
changes were linked to changes in growth control, since improved adaptation to growth
ability under modified culture conditions was observed [214]. The significance of
chromosomal alterations in different stages in cell transformation is not yet fully
established [214]. HaCaT cells exhibit unbalanced aneuploidy and their cytogenetic
changes are essential for the early disturbances in growth control resulting in prolonged
life span [214].
HaCaT cells malignantly transformed by chronic incubation in low concentration of
sodium arsenite are a very well-established in vitro model to study arsenic-induced skin
carcinogenesis. Specifically, continuous exposure of HaCaT cells to 100 nM of sodium
arsenite for 28 weeks induced malignant transformation [215] [161]. After 28 weeks of
chronic arsenic exposure, HaCaT cells exhibited unique morphological alterations with
frequent occurrence of giant multinuclear cells, which are common during malignant
transformation and are present in tumors [216]. Also, there was a marked increase in
secretion of active matrix metallopeptidase 9 (MMP-9) in arsenic-exposed cells and
MMP-9 extracellular activity was 2.3-fold higher in arsenic-treated cells compared to
control [161]. Arsenic-treated cells expressed higher levels of keratin-1, keratin-10,
involucrin and loricrin, which are markers of keratinocyte differentiation and skin
keratinization, compared to control cells [161]. Malignant transformation was further
confirmed after inoculation of these transformed cells into nude mice and the
development of aggressive squamous cell carcinoma (SCC) [215] [161]. Also, long-term
low dose exposure of HaCaT to sodium arsenite induces progressive aberrant DNA
methylation profile, associated with developing tumors in Balb/c mice [217]. Another
study showed that following sodium arsenite exposure for 30 passages, HaCaT cells
acquired a cancer stem-like phenotype [218]. Arsenic-treated cells also became
tumorigenic in nude mice compared to nontreated cells and they exhibited a higher
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growth rate and an increase in colony-forming efficiency [218]. The verification of
malignant transformation of HaCaT cells following chronic arsenic exposure was
performed after passage-matched HaCaT and arsenic-treated HaCaT cells were
intradermally injected into athymic nude mice [219]. None of the mice injected with the
parental HaCaT cells developed tumors at the injection site, while all injected mice with
arsenic-treated cells developed tumors, which expressed stem cell markers [219]. Also,
arsenic-treated cells were more invasive than nontransformed HaCaT cells in vitro [219].
Moreover, under regular growth conditions, lower concentrations of arsenic (0.05-0.5
μmol/L) increased HaCaT cell viability and proliferation while exposure to higher
concentrations (3 μmol/L) decreased cell viability and proliferation [220]. Thus, HaCaT is
a well-established model in the study of the effects of chronic arsenic exposure and its
association with skin carcinogenesis.
1.19 Chromosomal instability
Chromosomal instability (CIN) is defined as a form of genomic instability that leads
to both numerical and structural chromosomal alterations [221]. Healthy human cells
contain two sets of 23 chromosomes, one set inherited from each parent, having a total
of 46 chromosomes [222]. Euploid is the state of having 46 chromosomes while
aneuploidy is the state of having fewer or more chromosomes [222]. In other words,
aneuploidy is a state in which the number of chromosomes in a cell or organism deviates
from multiples of the haploid number of chromosomes [222] [221]. Numerical CIN
includes the gain or loss of whole chromosomes and can be due to mistakes in the
distribution of DNA to daughter cells during mitosis. Structural CIN is caused by gains,
losses or translocations or parts of one or multiple chromosomes, without necessarily
changing the number of chromosomes [222]. The generation of structural and numerical
abnormalities can be visible as mis-segregated chromosomal material during mitosis,
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where duplicated chromosomes are divided between the two daughter cells [223].
Several proteins regulate mitosis and assure accurate chromosome segregation,
however mistakes in mitosis can occur and lead to CIN [224]. For instance, errors in
attachment of spindle microtubules to a chromosome leads to mis-segregation of that
chromosome, leading to numerical chromosomal abnormality [224]. Additionally,
attachment of multiple spindle microtubules from opposing sides/daughter cells can “tear
apart” a chromosome, causing the two daughter cells to either gain or lose part of that
chromosome, leading to structural chromosomal abnormality [224] [223]. CIN can also
be caused by processes preceding mitosis, for instance due to faulty DNA damage,
repair or replication stress [225] [226].
There are different types of CIN, including chromosomal translocations, dicentric,
ring and double minute chromosomes. Specifically, a chromosomal translocation is a
type of chromosomal rearrangement in which two non-homologous chromosomes
exchange genetic material [227]. The process of exchange involves breakage of each
chromosome at a specific point (breakpoint), followed by fusion of the fragments
generated by these breaks [227]. A simple case is the reciprocal translocation between
two chromosomes; however, translocations can involve three or more chromosomes.
Also, if no genetic material is lost, translocations are known as “balanced” [227]. A
known example of a reciprocal translocation is in the case of chronic myelogenous
leukemia, in which there is the reciprocal translocation (t(9;22)(q34;911) [228]. This
translocation leads to the appearance of the Philadelphia chromosome and the BCRABL fusion gene consisting of the breakpoint cluster region (BCR) gene and abelson
murine leukemia viral oncogene homolog 1 (ABL1) gene. This fused gene codes for a
tyrosine kinase, which is targeted by tyrosine kinase inhibitors and thus achieving
remission of the disease [228].
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Dicentric chromosomes are products of genome rearrangement that places two
centromeres on the same chromosome [229]. Normally, each chromosome contains a
single region of centromeric DNA where the centromere and kinetochore are assembled
[229]. However, genome rearrangements can lead to fusion of two different
chromosomes, often resulting in a dicentric chromosome on which two centromeres are
linked [229]. Dicentric chromosomes can be quite stable in mitosis and inherited through
meiosis [229]. Dicentric’s stability can be due to centromere inactivation, where one of
the centromeres becomes nonfunctional or inactive and, in this case, a dicentric
chromosome segregates as a functionally monocentric chromosome during cell division
[230]. Inactive centromeres of dicentric chromosomes lack key centromere and
kinetochore proteins, such as histone H3-like centromeric proteins (CENP-A, CENP-C,
and CENP-E), however the mechanism of centromere inactivation remains unclear
[230]. Many dicentric chromosomes have been observed in humans and associated with
birth defects such as Turner Syndrome and Down Syndrome and with other reproductive
abnormalities [229]. Dicentrics can occur between any two chromosomes, but some
types are more prevalent than others [229]. For example, Robertsonian translocations
(ROBs) and isochromosome X i(X) [231]. ROBS involve any two of the ten acrocentric
chromosomes (13, 14, 15, 21, and 22) [231]. Rob(13;14) and rob(14;21) account for
approximately 85% of dicentric ROBs found [232]. ROBs are whole-arm transfers
between homologous or non-homologous chromosomes and they may be monocentric
or dicentric (in dicentric the second centromere is often inactivated) [232]. Dicentric
ROBs are the most common human chromosome abnormality, about 1/1000 in
newborns [232].
Ring chromosomes (RCs) are circular DNA molecules, typical for many prokaryotes,
eukaryotic plastids, and mitochondria but rare in the nucleus of eukaryotic genomes
[233]. McClintock and Rhoades noted that RCs are unstable in the cell cycle, can
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change their size, become lost or increase their copy number [234]. The presence of
RCs in humans often leads to abnormal development [233]. RCs are formed because of
two double-strand DNA breaks, for example after exposure to ultraviolet radiation [235]
or after nuclear disasters (the number of RC carriers increased after the Chernobyl
disaster) [236]. Two broken ends are combined and form a RC and chromosome ends
without centromere are lost [233]. The formation of RC by two double-strand DNA
breaks can lead to the loss of genetic material and gene monosomy [237]. Also, RCs
can be formed by the fusion of the telomeric or subtelomeric regions without loss of
genetic material, thus RC carriers are often healthy but have reduced fertility. [238]
[237]. Additionally, RCs formation can occur through inverted duplication associated with
a deletion (inv dup del rearrangements), which may be stabilized by circularization [233].
The frequency of RCs in the human population is about 1 in 50,000 embryos [239] and
about 50% of RC carriers do not have significant symptoms [240]. The clinical
manifestations of RCs are similar with corresponding syndromes induced by genetic
material deletion and accompanying monosomy [233].
Double minutes are extrachromosomal circular DNA (eccDNA) and found in the
context of chromothripsis, a catastrophic event in which one or a few chromosomes are
shattered into pieces, then reassembled in an unnatural order and orientation via nonhomologous end joining [241] [242]. Double minutes lack centromeres; thus, they are
unequally segregated to daughter cells at cell division [242]. EccDNA amplification can
increase copy number of oncogenes and significantly enhance and maintain tumor
heterogeneity [243]. Despite their important roles in tumorigenesis, it is unclear how
double minutes evolve and how they contribute to the dynamics of tumor heterogeneity
[243].
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Thus, there are many types of CIN and each of them is implicated in different
diseases. Mechanisms of CIN and types of CIN implicated in carcinogenesis are
described in the next section (1.20).
1.20 Mechanisms of chromosomal instability associated with carcinogenesis
Most solid tumors exhibit aneuploidy and aneuploidy was first associated with
tumors in the late 19th century [221]. Cancer CIN results in a high rate of change of
chromosome number and structure and generates intratumour heterogeneity [244]. The
majority of solid tumors exhibit CIN and it is associated with both poor prognosis and
therapeutic resistance [245]. Structural and numerical CIN are frequently found in solid
tumors [225] and this co-occurrence can be induced through defective mitotic checkpoint
function or chromosome attachment to the mitotic spindle, or via pre-mitotic defects such
as faulty DNA repair and replication [246].
There are various mechanisms through which tumor cells lose mitotic fidelity and
exhibit CIN [225]. Depletion of cohesins or of the cohesion regulators and separase
(which cleaves cohesion to initiate anaphase) using RNA interference increases the
numbers of tetraploid cells, frequently observed in tumor genomes [247]. Also, tetraploid
cells arise when separase is overexpressed, indicating that disturbances of cohesion
cause chromosome segregation errors in tumor cells [248]. For example, high levels of
separase are observed in breast cancer tumor samples, which exhibit CIN, compared
with normal tissue controls [249]. Additionally, large-scale sequencing of tumor genomes
shows that cohesin genes are rarely mutated [250]. Moreover, impairments of the
spindle assembly checkpoint (SAC) can significantly increase the likelihood for
chromosome mis-segregation, meaning that mutations in SAC genes can cause CIN
[221]. Some breast tumor cell lines have decreased levels of the SAC protein (mitotic
arrest deficient 2) MAD2 [251], and mutations in the gene encoding mitotic checkpoint
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serine/threonine kinase (BUB1) have been identified in colon cancer cell lines [252].
Experiments in mice support the association of CIN with defective SAC activity in
carcinogenesis. Heterozygous mice with mutations in specific SAC genes displayed
elevated chromosome mis-segregation rates compared with control animals and had
increased tumor incidence later in life [253] [254]. For example, mice heterozygous for
Mad2 gene mutations develop spontaneous lung tumors after 18 months [253] and mice
with hypomorphic Bub1 alleles display an increase in hepatocellular carcinomas, lung
adenocarcinomas, sarcomas, and lymphomas after 19 months [255]. These results of
tumor formation in many of these transgenic mouse models suggests that chromosomal
instability promotes tumorigenesis [221].
Another mechanism of chromosomal instability associated with carcinogenesis is
due to defects in kinetochore-microtubule attachment dynamics [221]. The centromerelocalized Aurora B kinase is a central controller of the regulation of kinetochoremicrotubule dynamics [221]. Inhibition of this kinase renders the attachment of
microtubules to kinetochores irreversible [256]. One of the targets of Aurora B is the
Ndc80 complex and members of the kinesin-13 family of microtubule-depolymerizing
enzymes [257]. Loss of function of these targets eliminates stable kinetochoremicrotubule attachments and contributes to CIN [221]. It was shown that kinetochoremicrotubule attachments were more stable in tumor cells with CIN than in a
chromosomally stable diploid cell line [257]. CIN cancer cells displayed hyperstable
kinetochore-microtubule attachments in prometaphase, or metaphase, or both [221].
Overexpression of kinesin-13 reduced kinetochore-microtubule attachment stability and
restored chromosome segregation to cancer cells that otherwise exhibited CIN [257].
This provides evidence that the excessively stable kinetochore-microtubule attachments
are the cause of CIN in many cancer cells [221]. Additionally, components of the
anaphase promoting complex (APC/C) are frequently mutated in cancer cells and these

44

cells show high rates of lagging chromosomes in metaphase [258]. Depletion of APC
increased kinetochore-microtubule stability and induced lagging chromosomes in stable
diploid cells [257]. The latter was rescued by overexpression of proteins that promoted
kinetochore-microtubule dynamics [257].
Defects in cell-cycle regulation can account for CIN observed in tumors [221]. For
example, F-box and WD repeat domain containing 7 (FBXW7) is a ubiquitin ligase that
targets cyclin E for degradation and thus regulates the G1-S cell cycle transition [259].
FBXW7 is mutated in many cancers, including ~12% of colorectal cancers which exhibit
CIN, however the role of FBXW7 in CIN remains unclear [259]. Another example is the
retinoblastoma (Rb) tumor suppressor protein, which regulates the transcriptional
activator E2F [260]. One target of E2F is the Mad2 gene and loss of Rb results in
overexpression of Mad2, which has been shown to include CIN [260].
Thus, CIN can occur due to defects in multiple levels of chromosomal regulation and
understanding the various mechanisms of CIN associated with carcinogenesis would be
crucial for diagnosis, prognosis and even therapeutic design.
1.21 Types of chromosomal instability associated with carcinogenesis
Different types of chromosomal instability are involved in carcinogenesis and many
different cancers display characteristic chromosomal abnormalities. This section is
focused on describing examples of dicentrics, rings, double minute chromosomes and
translocations and their implication in different malignancies.
Dicentric chromosomes have been identified in hematological malignancies,
including the recurrent dic(17;20) [261] and dic(5;17) [262] in myelodysplastic syndrome
(MDS) and acute myeloid leukemia (AML) as well as the dic(9;20) [263] in acute
lymphoblastic leukemia [264]. These dicentrics occur usually due to unbalanced
reciprocal translocations, with breakpoints often described at or near the centromere
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[265]. Most dicentric chromosomes appear to have a range of breakpoints on both
chromosomes, but the dic(9;20) has been shown to have breakpoints within a single
gene on 9p, PAX5, creating a fusion gene between this gene and a number of different
genes on 20q [266]. Thus, dicentric chromosomes frequently occur in various cancers
and may contribute to the malignant phenotype and clonal evolution [264].
Ring chromosomes (RCs) formation, formation of chromosome bridges,
isochromosomes, deletions, polyploidy etc. are present in many tumors [233].
Chromosomal abnormalities are a hallmark of cancer cells [233]. Specific
rearrangement, including RCs are frequently markers of tumors [233]. For example, fat
tissue tumors known as “atypical lipomas” and well-differentiated liposarcomas” often
have RCs [267]. Also, some tumors of mesenchymal origin exhibit RCs in more than
70% of cells [268]. Overall, RCs occur in approximately 10% of epithelial cancers and
less than 10% in hematopoietic neoplasias [268]. In leukemias, the presence of ring
chromosomes seems to be associated with poor prognosis in most but not all cases
[268]. The majority of hematopoietic neoplasias that exhibits RCs is acute nonlymphoblastic leukemia, in which the chromosomes forming the corresponding ring could
not be clearly defined [268]. RCs are very typical in certain low or borderline malignant
mesenchymal tumors, such as dermatofibrosarcoma protuberans, parosteal
osteosarcoma, low-grade malignant fibrous histiocytoma and atypical lipomatous tumors
[269]. Thus, RCs server as cytogenetic hallmarks and are used in determining proper
diagnosis [270].
Double minutes are frequently found in many different tumor types, especially in
brain tumors [271]. Double minutes are associated with resistance to targeted cancer
therapy [272]. G-banding revealed regions lacking patterns that might identify their origin
in other chromosomes of normal parental cell karyotypes [271]. Chromosome banding
applied to neuroblastoma cells led to the discovery of the homogenously staining regions
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(HSRs), which are distinctive regions stained uniformly [271]. HSRs were initially
described in human neuroblastoma and methotrexate-resistant hamster cells [273].
HSRs in methotrexate-resistant cells were considered to involve intrachromosomal
amplification of the dihydrofolate reductase gene, the target enzyme of methotrexate
[273]. Many reports imply a relationship between double minutes and HSRs [274]. Both
double minutes and HSRs display pale staining with G-banding [271]. Also, double
minutes and HSRs were reported as mutually exclusive since some cell lines contained
subpopulations with double minutes or HSRs but rarely both [275]. The latter suggests
that double minutes and HSRs were alternative manifestations of the same biological
phenomenon [271]. There is biochemical evidence supporting the relationship between
double minutes and HSRs [271]. In Chinese hamster cells stably resistant to
methotrexate, the gene for the target enzyme dihydrofolate reductase was amplified in
an HSR on chromosome 2 [276] [271]. In stably resistant mouse cells, HSRs were also
the chromosomal sites of dihydrofolate reductase gene amplification [277] [271]. On the
other hand, mouse cell lines unstably resistant to methotrexate contained unstably
amplified dihydrofolate reductase genes associated with double minutes [278]. These
reports correspond well with cytogenetic indications that HSRs were attached to
chromosomes with stable centromeres, while double minutes were without centromeres
[271]. Thus, gene amplification can be alternatively associated with chromosomal HSRs
in case of stable phenotypes or with double minutes in case of unstable phenotypes
[271].
Breast and ovarian cancers, but also various types of lung cancers and colon
carcinomas, showed the highest percentages of double minute positive cases (breast
cancer: 18%, ovarian cancer: 29%, colon cancer: 44%) [279]. Double minute
chromosomes were also observed in 20%-30% of small cell lung cancers (SCLC) and
10%- 20% of non-small cell lung cancers (NSCLC) [279]. There are also reports on the
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association of double minutes with MYC proto-oncogene (MYC) or epidermal growth
factor receptor (EGFR) amplification in some cases of lung cancer [280]. Specifically,
MYC amplification occurs in 15%-30% of SCLC and in 5%-10% of NSCLC [280].
Moreover, more than 20% of glioma cases are carriers of double minute positive cells
[279]. The amplified EGFR gene is the most frequently located on the double minute
positive cells in human gliomas [279]. Also, double minutes are very frequent in
neuroblastomas, approximately 30% of advanced tumor stages and they carry amplified
copies of the MYCN gene [281]. Additionally, Marinello et al reported that double minute
chromosomes occurred in 40 of 320 patients with hematologic diseases [282].
Amplification of MYC associated with double minutes frequently occurs in acute myeloid
leukemia (AML) and is linked with poor prognosis [279] [282].
There is evidence of a possible link between chromosomal instability and metastasis
[222]. Aneuploid tumors were more often a higher grade and stage and were associated
with decreased patient survival in several types of cancer [283] [284] [222]. A metaanalysis of 141,163 breast cancer cases showed that patients with aneuploid breast
cancer had worse survival compared to patients with a diploid tumor [285]. Also,
chromosomal instability was associated with breast cancer containing lymph node
metastasis [285]. A meta-analysis on colorectal cancer (CRC) indicated that aneuploidy
was linked to higher tumor stage in most of the studies analyzed [286]. Another study on
gastric cancer found an increase in aneuploidy in distant metastases [287]. Thus, there
is evidence of correlation of chromosomal instability and metastasis.

1.22 Metal-induced chromosomal instability as a driving force for carcinogenesis
Heavy metals are generally considered to be weak mutagens, if mutagenic at all
and CIN is reported to be the driving force for metal-induced carcinogenesis [288] [289].
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Exposure to chemical agents can destabilize the numbers and structure of
chromosomes, alter regulators of chromosome segregation, and disturb DNA synthesis
and repair [288]. Arsenic, cadmium, chromium, nickel, beryllium, and cobalt are
considered as carcinogenic metals and lead is also suggested as a probable carcinogen
[289]. A description of the association of various metals with carcinogenesis is following
in this section. A more detailed discussion of arsenic induced CIN as a mechanistic
event in carcinogenesis is in section 1.23.
Cadmium is an environmental contaminant and exposure to cadmium also occurs
through cigarette smoking [290]. It is a known human carcinogen, and cadmium
exposure increases the risk for lung, kidney, liver, bladder, stomach, and prostate
cancers [291]. Cadmium carcinogenesis has been linked to CIN and microsatellite
instability (MIN) [291]. Specifically, cadmium induces sister chromatid exchange and
inhibits mismatch repair activity in various cells [292] [291]. Cadmium also produces
depolymerization of the actin cytoskeleton in several cultured cell lines [293]. Finally,
cadmium also causes failure of kinetochores to attach to the spindle apparatus either by
alteration of its proteins or by altered chromatid separation in anaphase [294].
Hexavalent chromium is a well-established human lung and bladder carcinogen, but
the mechanism of chromium-induced carcinogenesis is not fully understood [289]. A
suggested key mechanism is that hexavalent chromium causes CIN, which further leads
to neoplastic transformation [295]. Specifically, studies show that chronic exposure to
hexavalent chromium impacts DNA repair and induces centrosome amplification, which
then leads to numerical and structural chromosomal abnormalities [295]. Hexavalent
chromium-induced lung and bladder tumors have been characterized by MIN and CIN
[295]. MIN was detected in 79% of chromium-induced lung tumors, while only 15% of
non-exposed lung tumors had increases in MIN [296]. Loss of heterozygosity (LOH) was
observed at 6 different loci in 50-75% of chromium-induced lung tumors, while this was
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not observed in non-exposed tumors [296]. Moreover, lymphocytes of chromate workers
exhibited increased CIN, as well as high number of bi-nucleated cells [297]. The latter is
consistent with cell culture studies showing increased bi-nucleated cells and changes in
chromosomes’ structure in various cell lines exposed to hexavalent chromium [298].
Also, cell culture studies have shown that exposure to hexavalent chromium for more
than 24 h, causes SAC bypass [299], centrosome amplification [300] and defects in the
homologous recombination (HR) pathway [301]. All of these can affect chromosomal
stability, causing numerical and structural aberrations. Xie et al 2007 showed that
bronchial cells malignantly transformed by lead chromate exhibited increased levels of
aneuploidy and centrosome amplification [302]. Long-term exposure to hexavalent
chromium also induced a concentration-dependent increase in aneuploid metaphases in
primary and immortalized human urothelial cells [303].
Beryllium has long been implicated in lung carcinogenesis; however, the mechanism
of beryllium-induced lung cancer remains unclear [289]. Some in vitro assays have
shown that beryllium suppresses the dynamic instability of microtubules [304],
suggesting a potential mechanism for an aneuploid effect [304].
Cobalt is considered a possible human lung carcinogen [289]. Cobalt chloride
induces aneuploidy in lymphocytes in the chromosomes 13, 14, 15, 21, 22 and Y [305].
Also, hamsters intraperitoneally injected with cobalt chloride exhibited aneuploidy in
bone marrow and testes [305]. Occupational exposure to cobalt refinery workers caused
increased chromosome loss [305]. The etiology of cobalt-induced CIN is unclear, but
DNA damage and repair inhibition are suggested mechanisms of CIN in carcinogenesis
due to cobalt exposure [305]. A study in human skin cells exposed to 2 ppb cobalt
chloride showed that keratinocytes exhibited increased aneuploidy (more than 46
chromosomes) compared with unexposed cells [306].
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Lead is a probable carcinogen and characterized as an aneugenic agent in both cell
cultures and epidemiologic studies [289] [307] [308]. A pilot study in Poland, consisting
of 9-year-old children (n=92) showed that exposure to lead causes increase in
micronuclei (MN) formation in their hematopoietic cells [308]. MN formation may
predispose these children to hematopoietic malignancies and was also correlated with
elevated blood lead levels [308]. Also, in Chinese hamster lung cell cultures inorganic
lead compounds caused micronuclei formation and aneuploidy [307]. The aneuploidy is
likely a result of destabilized microtubules causing the assembly/disassembly steady
state to shift to microtubule disassembly due to inhibition of tubulin assembly [307] [309]
[289].
Nickel is a carcinogenic metal causing lung and nasal cancers, mainly due to
occupational exposure [289]. Several studies have shown that nickel causes
chromosomal damage, but the mechanism of action remains unclear [289]. Specifically,
studies in human cells showed an increase of kinetochores positive micronuclei after 2426 h treatment of nickel sulfate and nickel chloride [310]. Another study showed that
after 72 h of exposure to nickel sulfate, hamster cells had increases in the production of
aneuploid metaphases, MN formation and an increase in cells exhibiting errors in
chromosome segregation, including lagging chromosomes, chromatin bridges and
asymmetrical segregation [311].
1.23 Arsenic-induced chromosomal instability as a driving force for
carcinogenesis

As mentioned in section 1.1, arsenic is clastogenic and it causes CIN both in vitro
and in vivo [3]. The molecular mechanism by which arsenic induces CIN-mediated
carcinogenesis is yet to be delineated. In section 1.8, suggested mechanisms of arsenic

51

induced CIN are described in detail. This section contains examples of how arsenic
causes CIN and its association with tumorigenesis.
Arsenic exposure is associated with lung, skin, liver, and bladder cancer [289].
Several studies have shown that arsenic causes CIN and disrupts the normal
progression of mitosis which can lead to polyploidy or structural chromosomal
abnormalities [312]. Specifically, chronic exposure to arsenic, both in vitro and in vivo,
results in structural changes, including chromosome end to end fusion, abnormal sister
chromatid separation, and aberrant chromosome segregation [117]. Arsenic induces
lagging chromosomes, suggesting a disruption of microtubule assembly dynamics [313].
Arsenic exposure may disrupt microtubule assembly through interaction with the
sulfhydryl groups of tubulins, leading to mitotic spindle complex malfunction [314] [315].
Arsenic also bypasses the SAC, resulting in premature anaphase and the induction of
diplochromosomes and tetraploidy in subsequent cell divisions [313]. Additionally,
arsenic can cause centrosome amplification and it has been detected through the
formation of multi polar spindles and immunofluorescent staining of centrosomes [316]
[312]. Arsenite induces mitotic arrest by disrupting centrosome function [317].
Specifically, arsenite disrupts heat sock proteins, involved in both kinetochore and
centrosome organization, increasing centrosome abnormalities, and inducing mitotic
arrest [317]. Also, arsenic exposure has long been known to induce MN which can
contain either whole chromosomes or fragments of chromosomes, as indicated by in situ
hybridization [109]. Specifically, exposure to arenite causes MN formation and
binucleated in human colon carcinoma cells in [318].
A study in Argentina and Chile examining chromosomal alterations in bladder tumor
DNA in 123 patients who had been exposed to arsenic in their drinking water, showed
that the total number of chromosomal alterations was higher in individuals exposed to
higher arsenic levels [319]. These chromosomal alterations were mostly observed in
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metastatic tumors, raising the possibility that bladder tumors from arsenic-exposed
patients may behave more aggressively than tumors from unexposed patients [319].
Additionally, dicentric chromosomes and DNA hypomethylation (which enhances CIN)
were observed in V79-CI3 Chinese hamster cells by short term exposure to 10 μM
sodium arsenite [320]. These chromosomal alterations persisted even after the exposure
was withdrawn and the CIN propagated within the cell population [320]. Arsenic exposed
individuals with Bowen’s disease (skin carcinoma in situ) were more likely to have
significantly higher CIN in their peripheral blood lymphocytes than individuals with
arsenic-induced non-malignant skin lesions [321]. Micronuclei formation was higher in
individuals with arsenic-induced Bowen’s disease compared to those with non-cancer
skin lesions [322]. There is also evidence that an increased frequency of chromosomal
aberrations in peripheral lymphocytes is predictive of increased risk of cancer [321]. The
increase of CIN in patients with Bowen’s disease is consistent with results of previous
studies performed in Taiwan and in Europe, which showed an association of CIN with
cancer risk in an arsenic-induced black foot disease region in Taiwan [323] and with
arsenic-induced stomach cancer in Central Europe [324].
Thus, there are various mechanisms by which arsenic causes CIN and there is
evidence of CIN in arsenic-induced tumors. Elucidation of the types of chromosomal
abnormalities caused by arsenic and how CIN drives the arsenic-induced
carcinogenesis, is crucial for a better understanding of arsenic toxicity and for
therapeutic design to treat arsenic-induced cancers.
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1.24 Aim of the thesis
Previous study of differential miRNA expression in squamous cell carcinoma (SCC)
caused by chronic arsenic exposure in drinking water relative to that of premalignant
hyperkeratotic lesions, showed that miR-186 was highly expressed in some SCC relative
to hyperkeratosis [325] (see section 1.13). Also, HaCaT cells that overexpressed miR186 and were exposed to sodium arenite showed increased levels of aneuploidy and
structural chromosomal abnormalities, including dicentric, rings and double minute
chromosomes, compared to vector control transfected and unexposed HaCaT cells [5].
Given the introduction of this thesis; specifically, the role of miR-186 in
carcinogenesis through regulation of cell cycle (see section 1.14) and the role of arsenicinduced CIN as a driver of carcinogenesis (see sections 1.8 and 1.23), the focus of my
master’s degree project was to assess the role of arsenic exposure and miR-186 in skin
carcinogenesis and chromosomal instability. Specifically, the hypothesis that miR-186
overexpression drives malignant transformation of HaCaT cells by induction of
chromosomal instability, is tested in my master’s degree research project. The methods
that were used to test this hypothesis are described in chapter 2.
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CHAPTER 2: MATERIALS AND METHODS

2.1 Cell culture
2.1.1 HaCaT cells and arsenite exposure
Human immortalized keratinocytes, HaCaT cells were the kind gift of the Dr. TaiHao
Quan (University of Michigan Ann Arbor). The identity of the cells was confirmed by STR
(Short Tandem Repeat) mapping (Genetica DNA Laboratories/LabCorp, Burlington, NC).
HaCaT cells were cultured in alpha modification of minimal essential medium (α-ΜΕΜ,
Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS)
(characterized, HyClone, Logan, UT, USA), 2 mM glutamine, 100 units/mL penicillin and
100 μg/mL streptomycin (GIBCO, Invitrogen, Carlsbad, CA, USA). HaCaT cells were
transfected with pEP-hsa-miR-186 expression vector (Cell Biolabs) or empty vector and
maintained with 0.9 μg/mL puromycin (P7255, Sigma-Aldrich, St Louis, MO, USA) [5].
The clones were isolated and characterized for hsa-miR-186 expression [5]. Three hsamiR-186 transfected clones with the highest expression and three empty vector
transfectants with lowest expression were selected for study [5]. The six clones were
propagated independently for 8 weeks in complete α-MEM with 0 or 100 nm sodium
arsenite (NaAsO2) (CAS 7784-46-5, ThermoFisher Scientific, Waltham, MA, USA) [5].
This concentration of NaAsO2 was selected based on the average blood arsenic level
observed in an epidemiological study in China where people used tube wells of high
concentration of arsenic [57]. Chronic arsenic intoxication and arsenic-induced skin
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lesions and epidermal cancers were observed in this population [35]. The six clones
cultured for 8 weeks were established from frozen stocks of cells and further propagated
until they reached 29 weeks (Figure 5).
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Figure 5: Schematic overview of chronic culture and exposure to 0 or 100 nM of NaAsO2
of vector control and hsa-miR186 overexpressing HaCaT cells. VC1-4, VC3-2a, VC3-2b
are the three vector control clones with the lowest miR-186 expression and S1-1, S1-3,
S3-1 are the three miR-186 transfected clones with the highest miR-186 expression
levels [5].
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Each clone was also exposed to 0 or 100 nM of NaAsO2 for 29 weeks (Figure 5).
So, there are twelve total cultures of the following four different conditions: 1) vector
control HaCaT + 0 nM NaAsO2, 2) vector control HaCaT+ 100 nM NaAsO2, 3) miR-186
transfected HaCaT + 0 nM NaAsO2, 4) miR-186 transfected HaCaT + 100 nM NaAsO2.
Cultures were grown at 37°C in humidified atmosphere of 95% air and 5% CO2. Cells
were passaged twice per week (every 3-4 days) and a million cells were plated per 100
mm dish at every passage. Every month, cells were frozen down at 1 x 106 cells/ml in
NuncTM cryovials and stored in liquid nitrogen.

2.1.2 HeLa cells
HeLa cells were cultured in DMEM (Dulbecco’s Modified Eagle Media)
(ThermoFisher Scientific) supplemented with 10% fetal bovine serum (FBS)
(characterized, HyClone, Logan, UT, USA), 2 mM glutamine, 100 units/mL penicillin and
100 μg/mL streptomycin (GIBCO, Invitrogen, Carlsbad, CA, USA). Cultures were grown
at 37°C in humidified atmosphere of 95% air and 5% CO2. Cells were passaged twice
per week (every 3-4 days) and a million cells were plated per 100 mm dish at every
passage. HeLa cells were used in triplicates as a positive control in soft agar colony
formation assay (see 2.6).

2.2 Cytogenetic analysis
HaCaT clones either transfected with empty vector or overexpressing hsa-miR-186
and exposed to 0 or 100 nM of NaAsO2, were seeded into 100 mm dishes with 7 mL
complete α-MEM. Cells were allowed to acclimate for 48 h and re-enter normal cell cycle
pattern. Cells were arrested at metaphase after addition of demecolchicine solution
(#D1925, Sigma, St. Louis, MO, USA) to final concentration of 0.2 μg/mL. The cultures
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were then incubated at 37°C for 1 h. At the end of treatment, media were collected to
include any loosely adherent mitotic cells. Then, after collecting the media, the attached
cells in the dish were washed with phosphate buffered saline (PBS) and dissociated with
0.25% trypsin /1 mM EDTA (Ethylenediaminetetraacetic acid). Media was added to the
trypsinized cells to stop the trypsin. The trypsinized cells with the collected media were
then added to the media collected prior to trypsinization (which includes the loosely
adherent cells). Then, cells were pelleted by centrifugation at 1000 rpm for 5 min at 4 °C.
The pellets were resuspended and incubated in 10 mL of 0.075 M potassium chloride
(KCL) hypotonic solution for 17 min to swell the cells and the nuclei. At the end of 17
min, 1 mL of freshly mixed methanol-glacial acetic acid (3:1, v:v) was added to the tubes
and cells collected by centrifugation at 1000 rpm for 5 min at 4 °C. Subsequently, pellets
were suspended gradually in 10 mL methanol-acetic acid and incubated at room
temperature for at least 20 min, collected by centrifugation at 1000 rpm for 5 min at 4 °C
and resuspended in methanol-acetic acid. Then, the cells were dropped on microscope
slides to provide a suitable density of metaphases for microscopic analysis.
2.2.1 Chromosomal damage staining
The goal is to stain solid chromosomes for the purpose of scoring chromosome
damage (ring chromosomes, double minutes, dicentrics) and/or aneuploidy. The slides
were stained with 5% Giemsa for 5 min and then washed several times in deionized
water, dried overnight and then sealed with microscope cover glass.

2.2.2 Karyotype analysis
The goal is to stain slides for G-banding of chromosomes. The banding pattern can
distinguish chromosomal abnormalities or structural rearrangements, such as deletions,
translocations, insertions, and inversions. G-banding involves trypsin treatment followed
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by staining with Giemsa or Wrights stain to create characteristic light and dark bands.
Trypsin degrades euchromatic histones in DNA. After Giemsa staining, highly
transcriptional active regions (euchromatin) which have low content of histones will
appear as light bands. Highly condensed chromatin with little or no transcriptional activity
(heterochromatin) will have a large portion of its histones, which will be digested by
trypsin allowing the dye to access to the DNA [326]. The heterochromatin will appear as
dark bands. Fetal bovine serum (FBS) is used to inactivate the trypsin activity prior to
staining [326]. Specifically, after the cells were fixed, slides were immersed in 0.063%
trypsin solution for 30-60 sec at pH 7.2. A 2% FBS wash followed to stop the trypsin
digestion. Then, the slides were rinsed with pH 7.0 Gurr’s buffer, followed by 70% and
95% ethanol dehydration and rinsed in pH 6.8 Gurr’s buffer solution. The slides were
then stained for 3 min with 5% Giemsa and slides were coverslipped with cytoseal.
Fifteen metaphases were karyotyped for each clone in 9 weeks and 29 weeks timepoint.
Metaphases were analyzed using an Olympus light microscope and karyotypes were
assembled using Applied Spectral Imaging software.
2.3 RNA extraction
Total RNA was extracted from cells using the mirVanaTM RNA Isolation Kit (Ambion,
ThermoFisher Scientific) according to the manufacturer’s instructions for small RNA
enrichment. RNA concentrations were determined using NanoDrop® Spectrophotometer
ND-1000 (ThermoFisher Scientific). RNA integrity (RIN) analysis was determined using
the Agilent RNA 6000 Pico Kit, Eukaryote, version 2.6 and the Agilent 2100 Bioanalyzer
(Agilent Technologies, Inc., Santa Clara, CA, USA). All samples had RIN number greater
than 9.
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2.4 Western blot analysis
Cells were lysed with a solution of 10 mM Tris-HCl pH 7.4, 1 mM disodium
ethylenediaminetetraacetic acid (Na2EDTA), 0.1% sodium dodecyl sulfate (SDS), 1 mM
phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium vanadate (Na3VO4) and 1x
protease inhibitor cocktail (Complete, Roche, Mannheim, Germany). Insoluble debris
was removed from lysates by sonication and centrifugation at 13,000 x g, at 4 °C for 15
min. Protein concentrations were determined with a bicinchoninic acid (BCA) assay
(ThermoFisher Scientific). Aliquots of 20 μg of total protein extracts were resolved by
electrophoresis in 4-20% CriterionTM TGXTM Precast gradient sodium dodecyl sulfate
polyacrylamide gel (SDS-PAGE) (Bio-Rad). The resolved proteins were transferred onto
polyvinylidene fluoride membrane (PVDF, Millipore). Staining with Coomassie Brilliant
Blue R250 (ThermoFisher Scientific) followed, to ensure loading and transfer of proteins.
Membranes were then blocked in 5% milk in TBST (10 mM Tris-HCl pH 7.4, 150 mM
NaCl, 0.1% Tween 20) at room temperature for 1 h. The membranes were subsequently
probed with antibodies against BUB1 (#ab195268, Abcam, Cambridge, United Kingdom,
1:1000 in 1% skim milk powder in TBST), CDC27 (#ab129085, Abcam, 1:1000 in 1%
milk in TBST), BUBR1 (#ab183496, Abcam, 1:1000 in 1% milk in TBST), vimentin
(#5741T, Cell Signaling, Danvers, MA, USA, 1:1000 in 1% milk in TBST), n-cadherin
(#13116, Cell Signaling, 1:2000 in 1% milk in TBST), slug (#9585, Cell Signaling, 1:2000
in 1% milk in TBSTS), ZO-1 (#8193, Cell Signaling, 1:2000 in 1% milk in TBST), βcatenin (#8480, Cell Signaling, 1:2000 in 1% milk in TBST), e-cadherin (#3195T, Cell
Signaling, 1:3000 in 1% milk in TBST), claudin 1 (#13255, Cell Signaling, 1:1000 in 1%
milk in TBST), beta actin (#A5441, Sigma-Aldrich, 1:10000 in 1% milk in TBST) and
vinculin (#13901P, Cell Signaling, 1:1000 in 1% milk in TBST). Blots were then
incubated with anti-rabbit (#7074, Cell Signaling Technology, 1:1000 in 1% milk in
TBST) and anti-mouse (#7076, Cell Signaling Technology, 1:1000 in 1% milk in TBST)
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HRP-conjugated secondary antibodies as appropriate. Restore TM Western Blot
Stripping Buffer (#21059, ThermoFisher Scientific) was used for stripping between
probing with different antibodies. For the detection of signals, blots were incubated with
an enhanced chemiluminescent substrate (ECL) (ThermoFisher Scientific). Images were
acquired using FOTO/Analyst FX. Densitometry analysis was performed using Image
Studio Lite Software version 5.2.5.
2.5 Flow cytometry cell cycle assay
HaCaT clones either transfected with empty vector or overexpressing hsa-miR-186
were seeded at density of 1.5 million cells per 100 mm dish and exposed to 0 or 100 nM
NaAsO2. After 48 hours, the cells were trypsinized, washed twice with phosphate
buffered saline (PBS) then fixed in 70% ethanol for 24 hours at 4°C. The cells were then
centrifuged at 1500 g for 1 minute, suspended in PBS (400 μl), then RNAase A (10
mg/mL, 50 μL) and propidium iodide (2 mg/mL, 10 μL) were added followed by a 30
minute incubation in the dark at room temperature. Fluorescence was acquired by flow
cytometry on a Becton Dickinson FACSCaliburTM (BD Biosciences). Cell cycle
distribution was determined using FlowJo™ v10.2 [327].
2.6 Soft agar colony formation assay
Anchorage-independent growth is one of the hallmarks of cell transformation and is
considered an accurate in vitro assay for detecting malignant transformation [328]. The
soft agar colony formation assay is a common method to monitor anchorage
independence [328]. It measures proliferation in semisolid culture media after 6-8 weeks
by manual counting of colonies. Clones were analyzed at 12, 16, 20, 24 and 29-week
timepoints for transformation by colony formation in agar. Three dishes were seeded for
each clone. Hela cells, which are known to be malignant cells, were used a positive
control. Control and treated clonal cell lines were suspended in 0.4% noble agar onto a
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0.8% noble agar base layer in a 30-mm dish at a density of 100,000 cells per dish for
HaCaT cells and 30,000 cells per dish for Hela cells and grown for 6-8 weeks. The top
and bottom agar layers were made at two times the final concentration in water and
diluted 1:1 with 2x concentrated media at the time of plating. Cultures were examined
microscopically 24 hours after plating to confirm single cell suspension. During
incubation in agar, old media was aspirated, and 0.5 mL of fresh growth media with 0 or
100 nM sodium arsenite was added to the cells twice per week. Colonies were detected
by 0.01% crystal violet staining and counted (
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Figure 6).

Figure 6: Schematic overview of the protocol for the soft agar colony formation assay
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2.7 Mycoplasma PCR assay
MycoSensor PCR Assay kit (#302108, #302109) (Agilent) was used to screen for
mycoplasma infection of cell cultures. HaCaT cells transfected with pEP-hsa-miR-186
expression vector or empty vector cultured for 29 weeks and exposed to 0 or 100 nM of
NaAsO2, were tested for Mycoplasma contamination. Fifty μL of test cell culture media,
50 μL of negative control (deionized water) and 50 μL of positive control media (provided
by the kit) were used as PCR templates. PCR was performed according to
manufacturer’s instructions.

2.8 Statistical analysis
Protein expression data were analyzed with two-way ANOVA and Tukey’s post-hoc
test (for multiple comparisons). Data are expressed as mean +/- SD (Standard
Deviation). The level of significance was established at p value ≤ 0.05. The statistical
analyses were all conducted using GraphPad Prism 8.4.2 (679)
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CHAPTER 3: RESULTS
3.1 Soft agar colony formation assay
The ability of cells to proliferate in suspension, unattached to any matrix, is a
characteristic of transformed cells, correlating with tumorigenic potential in vivo. HaCaT
overexpressing miR-186 and exposed or not to arsenic were tested in vitro for
anchorage-independent growth in agar [328]. The assay was performed at an early time
point (12 weeks) and at a late time point (29 weeks) to assess if miR-186
overexpression accelerates the arsenic transformation process. We observed that
HaCaT overexpressing miR-186 and exposed to arsenite showed increased growth
ability in agar at 12 weeks in contrast to vector control unexposed and exposed cells
(Panel A, Figure 7). Specifically, single cells formed clusters of cells in all miR-186
transfected clones also exposed to arsenite (S1-1, S1-3, S3-1), as indicated by red
arrows (Panel A, Figure 7). We also observed that all arsenite-exposed cells formed
colonies in agar at 29 weeks (Panel B, Figure 7). Specifically, single cells formed
colonies (more than 50 cells [329]) in agar in vector control and exposed to arsenite
clones (VC1-4, VC3-2a, VC3-2b) as well as in miR-186 overexpressing and exposed to
arsenite clones (S1-1, S1-3, S3-1), as indicated by red arrows (Panel B, Figure 7).
Specifically, we visually observed (not measured) that the miR-186 overexpressing cells
and exposed to arsenite formed slightly bigger colonies (as observed visually) compared
with vector control and exposed to arsenite clones (Panel B, Figure 7). No quantification
of data nor statistical analysis were performed since only one colony was formed per
replicate.
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Figure 7: Soft agar colony formation assay. Representative phase contrast images,
using 10x magnification: VC: Vector Control HaCaT, VC1-4, VC3-2a, VC3-2b are the
three vector control clones (see section 2.1.1), S: miR-186 overexpressing HaCaT, S1-1,
S1-3, S3-1 are the three miR-186 overexpressing clones (see section 2.1.1), A. HaCaT
overexpressing miR-186 and exposed to arsenite formed clusters of cells indicating
ability to grow in agar at 12 weeks, B. HaCaT transfected with vector control and
exposed to arsenite and HaCaT overexpressing miR-186 and exposed to arsenite
formed colonies from single cells at 29 weeks.
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We used HeLa cells as positive control because they are known transformed cells
and they formed multiple big colonies in agar, as it is shown after staining with crystal
violet 0.01% (Figure 8).
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Figure 8: HeLa cells as positive control. A. Representative colonies formed from single
cells in agar, stained with 0.01% crystal violet. Image was taken using dissecting
microscope. B. Representative image of a colony. Image was taken using phase
contrast microscope and 10x magnification.
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3.2 Protein levels of epithelial-mesenchymal transition
The results from the soft agar colony formation assay (see section 3.1) showed that
HaCaT overexpressing miR-186 and exposed to arsenite exhibited increased growth
ability in agar at 12 weeks in contrast to vector control cells (exposed or not to arsenite)
(Panel A, Figure 7). The soft agar assay also showed that colonies were formed in
HaCaT transfected with vector control and exposed to arsenite clones as well as in
HaCaT overexpressing miR-186 and exposed to arsenite clones at 29 weeks (Panel B,
Figure 7). In this section, we present another assay to assess the transformation
potential of these cells.
The induction of epithelial-to-mesenchymal transition (EMT) is an important
mechanism for the progression of carcinomas to a metastatic stage [330]. During EMT,
the levels of the epithelial markers are suppressed, and the levels of the mesenchymal
markers are induced [330]. We screened HaCaT cells overexpressing miR-186 and
exposed or not to arsenite, for the expression levels of epithelial and mesenchymal
markers. This approach might elucidate the association of miR-186 overexpression with
the progression to carcinoma.
We first determined the levels of the epithelial markers e-cadherin, β-catenin,
claudin 1, and ZO-1 [330]. Then, we determined the levels of the mesenchymal markers
n-cadherin and slug [330]. We also screened for the mesenchymal marker vimentin
[330], but this protein was not expressed in our cell line. At 29 weeks, the miR-186
transfected HaCaT cells and unexposed to arsenite include protein expression data only
from two clones (S1-1, S3-1, see section 2.1.1), because the S1-3 clone did not produce
enough cells for protein lysate collection.
After 12 weeks of culturing and exposing to 0 or 100 nM sodium arsenite three
clones of HaCaT cells transfected with vector control and three clones of HaCaT
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overexpressing miR-186 (see section 2.1.1), we observed no significant changes in
expression of the epithelial markers e-cadherin, claudin 1, β-catenin, and ZO-1, in vector
control and miR-186 overexpressing HaCaT cells, both in arsenite (100 nM) exposed
and unexposed cells (Figure 9).
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Figure 9 : Western blots for epithelial markers at 12 weeks. A. Western blots for ecadherin, claudin 1, β-catenin, ZO-1, and β-actin in HaCaT transfected with either vector
control or vector overexpressing miR-186 and exposed to 0 or 100 nM sodium arsenite
for 12 weeks, B. Quantification of e-cadherin relative to β-actin by densitometric
analysis, C. Quantification of claudin 1 relative to β-actin by densitometric analysis, D.
Quantification of β-catenin relative to β-actin by densitometric analysis, E. Quantification
of ZO-1 relative to β-actin by densitometric analysis. Data are represented as the % of
the mean unexposed control expression. Western blot and quantification show no
significant changes in expression of e-cadherin, claudin 1, β-catenin, and ZO-1, in vector
control and miR-186 overexpressing HaCaT, at 12 weeks. No difference was observed
when grouping all the miR-186 overexpressing cells versus the vector control cells. Data
are expressed as mean +/- SD. Data were analyzed with two-way ANOVA and Tukey’s
multiple comparison post hoc test.
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Then, we screened the expression levels of mesenchymal markers. Specifically, at
12 weeks, we observed no significant changes in expression of the mesenchymal
marker n-cadherin, and slug in vector control and miR-186 overexpressing HaCaT cells,
both in arsenite exposed (100 nM) and unexposed cells (
Figure 10).
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Figure 10 : Western blots for mesenchymal markers at 12 weeks. A. Western blots for ncadherin, slug, and β-actin in HaCaT transfected with either vector control or vector
overexpressing miR-186 and exposed to 0 or 100 nM sodium arsenite for 12 weeks, B.
Quantification of n-cadherin relative to β-actin by densitometric analysis, C.
Quantification of slug relative to β-actin by densitometric analysis. Data are represented
as the % of the mean unexposed control expression. Western blot and quantification
show no significant changes in expression of n-cadherin and slug in vector control and
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miR-186 overexpressing HaCaT, at 12 weeks. Data are expressed as mean +/- SD.
Data are analyzed with two-way ANOVA and Tukey’s multiple comparison post hoc test.
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After 29 weeks of culturing three clones of HaCaT cells transfected with vector
control and three clones of HaCaT overexpressing miR-186 and 0 or 100 nM sodium
arsenite exposure (see section 2.1.1), we observed that the expression of the epithelial
marker e-cadherin is significantly decreased in miR-186 overexpressing and exposed to
arsenite HaCaT cells (p <0.05), compared to unexposed vector control HaCaT cells
(Panel B, Figure 11). Also, the levels of e-cadherin are significantly decreased in miR186 overexpressing and exposed to arsenite HaCaT cells (p <0.05), compared to miR186 overexpressing HaCaT cells which were not exposed to arsenite (Panel B, Figure
11). Also, at 29 weeks, we observed that the expression of the epithelial marker claudin
1 is decreased in all arsenite exposed (100 nM) cells (vector control transfected HaCaT
and miR-186 overexpressing cells) (Panel C, Figure 11). Specifically, the protein levels
of claudin-1 are significantly decreased (p <0.05) in miR-186 overexpressing HaCaT
cells and exposed to arsenite (100 nM) compared to unexposed vector control HaCaT
cells (Panel C, Figure 11). Additionally, at 29 weeks, we observed that the expression of
the epithelial marker β-catenin is significantly decreased in vector control and exposed to
arsenite (100 nM) HaCaT cells (p <0.05), compared to unexposed vector control HaCaT
cells (Panel D, Figure 11). Also, the protein levels of β-catenin are more significantly
decreased in miR-186 overexpressing HaCaT cells and exposed to arsenite (100 nM) (p
<0.01), compared to unexposed vector control (Panel D, Figure 11). At 29 weeks, we
also observed no significant changes in the expression of the epithelial marker ZO-1 in
vector control HaCaT cells and miR-186 overexpressing HaCaT cells, both in exposed
(100 nM) and unexposed cells (Panel E, Figure 11).
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Figure 11 : Western blots for epithelial markers at 29 weeks. Western blots for ecadherin, claudin 1, β-catenin, ZO-1, and β-actin in HaCaT transfected with either vector
control or vector overexpressing miR-186 and exposed to 0 or 100 nM sodium arsenite
for 29 weeks, B. Quantification of e-cadherin relative to β-actin by densitometric
analysis. Western blot and quantification show that the expression of e-cadherin is
significantly (p <0.05) decreased in miR-186 overexpressing HaCaT exposed to arsenite
compared to unexposed vector control and compared to miR-186 overexpressing
HaCaT unexposed to arsenite, at 29 weeks, C. Quantification of claudin 1 relative to βactin by densitometric analysis. Western blot and quantification show that the expression
of claudin 1 is significantly (p <0.05) decreased in miR-186 overexpressing HaCaT
exposed to arsenite compared to unexposed vector control, at 29 weeks, D.
Quantification of β-catenin relative to β-actin by densitometric analysis. Western blot and
quantification show that the expression of β-catenin is significantly (p <0.05) decreased
in vector control exposed to arsenite HaCaT cells compared to unexposed vector control
and it is more significantly (p <0.01) decreased in miR-186 overexpressing HaCaT
exposed to arsenite compared to unexposed vector control, at 29 weeks, E.
Quantification of ZO-1 relative to β-actin by densitometric analysis. Western blot and
quantification show no significant changes in expression of ZO-1 in vector control and
miR-186 overexpressing HaCaT, at 29 weeks. Data are represented as the % of the
mean unexposed control expression Data are expressed as mean +/- SD. Data are
analyzed with two-way ANOVA and Tukey’s multiple comparison post hoc test. The level
of significance is established at p value ≤ 0.05, *p <0.05. At 29 weeks, the miR-186
transfected HaCaT cells and unexposed to arsenite include protein expression data only
from two clones (S1-1, S3-1, see section 2.1.1), because the S1-3 clone did not produce
enough cells for protein lysate collection.
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Then, we screened the expression levels of mesenchymal markers. Specifically, at
29 weeks, we observed that the expression of the mesenchymal protein n-cadherin is
significantly increased in miR-186 overexpressing HaCaT cells and exposed to arsenite
(100 nM) (p <0.05), compared to unexposed vector control HaCaT cells (Panel B, Figure
12). Finally, we observed at 29 weeks, that the expression levels of the mesenchymal
marker slug are significantly increased in miR-186 overexpressing HaCaT cells and
exposed to arsenite (100 nM) (p <0.05), compared to unexposed vector control HaCaT
cells (Panel C, Figure 12). Also, the protein levels of slug were more significantly
decreased in miR-186 overexpressing HaCaT cells and exposed to arsenite (100 nM) (p
<0.01), compared to vector control HaCaT cells and exposed to arsenite (100 nM)
(Panel C, Figure 12). Similarly, the levels of slug were significantly decreased in miR186 overexpressing HaCaT cells and exposed to arsenite (100 nM) (p <0.05), compared
to miR-186 overexpressing HaCaT unexposed to arsenite (Panel C, Figure 12).
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Figure 12 : Western blots for mesenchymal markers at 29 weeks. Western blots for ncadherin, slug, and β-actin in HaCaT transfected with either vector control or vector
overexpressing miR-186 and exposed to 0 or 100 nM sodium arsenite for 29 weeks, B.
Quantification of n-cadherin relative to β-actin by densitometric analysis. Western blot
and quantification show that the expression of n-cadherin is significantly (p <0.05)
increased in miR-186 overexpressing HaCaT exposed to arsenite compared to
unexposed vector control, at 29 weeks, C. Quantification of slug relative to β-actin by
densitometric analysis. Western blot and quantification show that the expression of slug
is significantly (p <0.05) increased in miR-186 overexpressing HaCaT exposed to
arsenite compared to unexposed vector control, compared to vector control HaCaT

81

exposed to arsenite (p <0.01) and compared to miR-186 overexpressing HaCAT
unexposed to arsenite (p <0.05), at 29 weeks. Data are represented as the % of the
mean unexposed control expression. Data are expressed as mean +/- SD. Data are
analyzed with two-way ANOVA and Tukey’s multiple comparison post hoc test. The level
of significance is established at p value ≤ 0.05, *p <0.05, **p <0.01. At 29 weeks, the
miR-186 transfected HaCaT cells and unexposed to arsenite include protein expression
data only from two clones (S1-1, S3-1, see section 2.1.1), because the S1-3 clone did
not produce enough cells for protein lysate collection.
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Overall, we observed that all epithelial markers (e-cadherin, β-catenin, claudin 1)
examined, apart from ZO-1, were suppressed at 29 weeks in HaCaT overexpressing
miR-186 and exposed to arsenite (100 nM) compared to unexposed vector control. Also,
both mesenchymal markers (n-cadherin, slug) tested, were induced at 29 weeks in
HaCaT overexpressing miR-186 and exposed to arsenite (100 nM) compared to
unexposed vector control. We did not observe any changes in any sample at 12 weeks.
These observations suggest that HaCaT transfected with miR-186 and exposed to
arsenite for 29 weeks undergo EMT.

3.3 Flow cytometry for cell cycle analysis
The results from the soft agar colony formation assay (see section 3.1) showed that
HaCaT overexpressing miR-186 and exposed to arsenite exhibited increased growth
ability in agar at 12 weeks in contrast to vector control cells (exposed or not to arsenite)
(Panel A, Figure 7). The soft agar assay also showed that colonies were formed in
HaCaT transfected with vector control and exposed to arsenite clones as well as in
HaCaT overexpressing miR-186 and exposed to arsenite clones at 29 weeks (Panel B,
Figure 7). Additionally, the western blot analysis for epithelial and mesenchymal markers
at 29 weeks, showed that HaCaT overexpressing miR-186 and exposed to arsenite had
reduced levels or epithelial markers (see section 3.2) (Panels A, B, C, D, Figure 11) and
increased levels of mesenchymal markers (see section 3.2) (Panels A, B, C, Figure 12).
Thus, there is an indication that these cells acquire hallmarks of malignant
transformation, and specifically the transformation process might be accelerated when
the cells overexpress miR-186 and are exposed to sodium arsenite simultaneously.
Cell cycle dysregulation underlies the aberrant cell proliferation that characterizes
cancer cells, and loss of cell cycle checkpoint control promotes chromosomal instability
[331]. The focus of this thesis is to assess the role of arsenic exposure and miR-186

83

overexpression in chromosomal instability as a driver force of skin carcinogenesis. Thus,
we wanted to determine if there are any changes in the cell cycle patterns of our three
clones of HaCaT cells transfected with vector control and three clones of HaCaT
overexpressing miR-186 (see section 2.1.1), either exposed to 0 or to 100 nM sodium
arsenite. For this purpose, we performed a flow cytometry analysis as described in
section 2.5 of the methods, at 14 weeks (an intermediated time point during our chronic
cell culture for 29 weeks). No changes in the cell cycle patterns were found, but we
observed that all the six clones exposed to 0 or 100 nM sodium arsenite exhibited similar
levels of aneuploidy (Figure 13).
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Figure 13 : Flow cytometry for cell cycle analysis. X-axis: DNA content from fluorescence
emission (FL2-H channel) after propidium iodide staining, y-axis: count (intensity) A.
vector clone (VC1-4) exposed to 0 nM (left) or 100 nM (right) sodium arsenite, B. vector
control clone (VC3-2a) exposed to 0 nM (left) or 100 nM (right) sodium arsenite, C.
vector control clone (VC3-2b) exposed to 0 nM (left) or 100 nM (right) sodium arsenite,
D. miR-186 overexpressing clone (S1-1) exposed to 0 nM (left) or 100 nM (right) sodium
arsenite, E. miR-186 overexpressing clone (S1-3) exposed to 0 nM (left) or 100 nM
(right) sodium arsenite, F. miR-186 overexpressing clone (S3-1) exposed to 0 nM (left)
or 100 nM (right) sodium arsenite. Approximately, 22%-35% cells in each clone,
exposed to 0 or 100 nM of sodium arsenite for 14 weeks, exhibited aneuploidy, as
indicated in the aneuploid S-phase of the histograms. No statistical difference was
observed between any of the clones.
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Specifically, 22%-35% cells in each clone, exhibited aneuploidy, as indicated by the
percentage of cells with aneuploid DNA content, observed in the aneuploid phase of the
histograms (Figure 13).
These data suggest that HaCaT transfected with vector control or overexpressing
miR-186 and exposed to 0 or 100 nM sodium arsenite have increased levels of
chromosomal instability, that could contribute to their transformation process. Thus, we
wanted to further determine the specific types of chromosomal instability that occur and
to investigate how arsenic exposure, miR-186 or the combination of both treatments
leads to chromosomal instability during carcinogenesis.
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3.4 Protein levels of cell cycle proteins
Bioinformatic analysis using the DIANA miRPath V3.0, has shown that miR-186 is
predicted to target mRNAs of proteins that regulate the cell cycle and are components of
the spindle assembly checkpoint (SAC) and anaphase promoting complex (APC),
including: budding uninhibited by benzimidazoles 1 (BUB1), and cell division cycle 27,
(CDC27) [194] (see section 1.15). According to the bioinformatic prediction, miR-186
targets and suppresses BUB1 and CDC27, which play a role in the establishment of the
mitotic spindle checkpoint and proper chromosome segregation. Also, ectopic
expression of miR-186 in HaCaT cells induces significant increase in numerical and
structural chromosomal abnormalities and these aberrations are further increased with
chronic arsenite exposure at 8 weeks of culture [5].
The focus of this thesis is to assess the role of arsenic exposure and miR-186 in
chromosomal instability and skin carcinogenesis. As described in sections 3.1 and 3.2,
there is indication that HaCaT overexpressing miR-186 and exposed to arsenite for 29
weeks acquire hallmarks of malignant transformation. Also, we observed that all vector
control and miR-186 overexpressing clones exhibited aneuploidy based on the results of
PI flow cytometry analysis (see section 3.3). Thus, we wanted to validate if the levels of
cell cycle proteins, which are crucial for proper chromosome segregation, are
dysregulated, because of miR-186 overexpression and arsenite exposure. Thus, we
tested the protein levels of two predicted targets of miR-186: BUB1 and CDC27, after 12
and 29 weeks of arsenite exposure. Also, we determined the protein levels of a
downstream target of BUB1, the BUB1-related protein 1 (BUBR1), which is also a crucial
component of the spindle assembly checkpoint (see section 1.16).
At 12 weeks, we did not observe any significant difference in BUB1, CDC27, or
BUBR1 levels, in vector control and miR-186 overexpressing HaCaT clones (Figure 14).
BUB1 protein levels were modestly increased in the arsenite exposed clones (100 nM),
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when compared with the unexposed clones, (p arsenite =0.043 < 0.05) (Panels A, B, Figure
14).
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Figure 14 :Western blots for cell cycle proteins at 12 weeks. Western blots for BUB1,
CDC27, BUBR1, and vinculin in HaCaT transfected with either vector control or vector
overexpressing miR-186 and exposed to 0 or 100 nM sodium arsenite for 12 weeks, B.
Quantification of BUB1 relative to vinculin by densitometric analysis. Western blot and
quantification show that the levels of BUB1 are slightly increased in all arsenite exposed
cells (100 nM), (p arsenite =0.043 < 0.05), at 12 weeks, C. Quantification of CDC27 relative
to vinculin by densitometric analysis. Western blot and quantification show no significant
changes in expression of CDC27 in vector control and miR-186 overexpressing HaCaT,
at 12 weeks, D. Quantification of BUBR1 relative to vinculin by densitometric analysis.
Western blot and quantification show no significant changes in expression of BUBR1 in
vector control and miR-186 overexpressing HaCaT, at 12 weeks. E. Quantification of the
ratio of phosphorylated BUBR1 to total BUR1, relative to vinculin by densitometric
analysis. Western blot and quantification show no significant changes in the levels of
phosphorylated BUBR1 in vector control and miR-186 overexpressing HaCaT, at 12
weeks. Data are represented as the % of the mean unexposed control expression Data
are expressed as mean +/- SD. Data are analyzed with two-way ANOVA and Tukey’s
multiple comparison post hoc test. The level of significance is established at p value ≤
0.05.
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Also, CDC27 protein levels did not change significantly in all vector control and miR-186
overexpressing HaCaT clones, at 12 weeks (Panels A, C, Figure 14). Similarly, the
levels of BUBR1 were slightly reduced in vector control and exposed (100 nM) cells, as
well as in miR-186 overexpressing and unexposed cells, , but this difference was not
statistically significant (Panels A, D, Figure 14). Additionally, the levels of the
phosphorylated BUBR1 were slightly reduced in miR-186 overexpressing cells exposed
to 0 or 100 nM sodium arsenite, however no significant changes were observed at 12
weeks (Panels A, E, Figure 14).
At 29 weeks, we did not observe any significant difference in BUB1 levels, in vector
control and miR-186 overexpressing HaCaT clones (Figure 14). Overall, BUB1 protein
levels were stable in all clones (Panels A, B, Figure 15). CDC27 protein levels were
increased in all arsenite exposed cells (100 nM), when compared with the unexposed
clones, (p arsenite =0.01 < 0.05), at 29 weeks (Panels, A, C, Figure 15). Although the
levels of BUBR1 in HaCaT overexpressing miR-186 and exposed to arsenite appeared
slightly increased, the difference was not statistically significant, when compared to
unexposed vector control cells, at 29 weeks (Panels, A, D, Figure 15). Also, the
phosphorylated levels of BUBR1 did not significantly change, but we observed a slight
decrease in the vector control and exposed to arsenite (100 nM) cells compared to
unexposed cells (Panels, A, E, Figure 15).
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Figure 15 : Western blots for cell cycle proteins at 29 weeks. Western blots for BUB1,
CDC27, BUBR1, and vinculin in HaCaT transfected with either vector control or vector
overexpressing miR-186 and exposed to 0 or 100 nM sodium arsenite for 29 weeks, B.
Quantification of BUB1 relative to vinculin by densitometric analysis. Western blot and
quantification show no significant changes in expression of BUB1 in vector control and
miR-186 overexpressing HaCaT, at 29 weeks, C. Quantification of CDC27 relative to
vinculin by densitometric analysis. Western blot and quantification show that the levels of
CDC27 are slightly increased in all arsenite exposed cells (100 nM), (p arsenite =0.01 <
0.05), at 29 weeks, D. Quantification of BUBR1 relative to vinculin by densitometric
analysis. Western blot and quantification show no significant changes in expression of
BUBR1 in vector control and miR-186 overexpressing HaCaT, at 29 weeks. E.
Quantification of the ratio of phosphorylated BUBR1 to total BUR1, relative to vinculin by
densitometric analysis. Western blot and quantification show no significant changes in
the levels of phosphorylated BUBR1 in vector control and miR-186 overexpressing
HaCaT, at 29 weeks. Data are represented as the % of the mean control expression.
Data are expressed as mean +/- SD. Data are analyzed with two-way ANOVA and
Tukey’s multiple comparison post hoc test. The level of significance is established at p
value ≤ 0.05. At 29 weeks, the miR-186 transfected HaCaT cells and unexposed to
arsenite include protein expression data only from two clones (S1-1, S3-1, see section
2.1.1), because the S1-3 clone did not produce enough cells for protein lysate collection.
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3.5 Cytogenetic analysis for numerical and structural chromosomal alterations
HaCaT overexpressing miR-186 and exposed to arsenite for 29 weeks acquire
hallmarks of malignant transformation (see sections 3.1 and 3.2). We also observed by
flow cytometry that all vector control and miR-186 overexpressing clones exhibited
aneuploidy (see section 3.3). Also, chromosomal instability is a hallmark of
carcinogenesis (see sections 1.19, 1.20) and the role of miR-186 in carcinogenesis via
regulation of cell cycle has been reported (see section 1.14). As mentioned in section
1.1, arsenic is clastogenic and it causes CIN both in vitro and in vivo [3] but the
molecular mechanism by which arsenic induces CIN-mediated carcinogenesis is yet to
be delineated (see section 1.23). Thus, we wanted to screen for specific structural and
numerical chromosomal abnormalities due to arsenic exposure, miR-186 overexpression
or combination of both treatments, that could drive transformation process of HaCaT
overexpressing miR-186 and exposed to arsenite (100 nM). For this purpose, we
performed karyotypic analysis at 9 weeks of culture, as described in section 2.2.2 of
methods. HaCaT cells already have endogenous levels of chromosomal aberrations
(see section 1.18). HaCaT cells are hypotetraploid with a range of 72-88 chromosomes,
and the presence of marker chromosomes M1: t(3q4q), M2: i[9q], and M4: [4p18q] (see
section 1.18). We validated the authenticity of the cell line by observing the presence of
marker chromosomes. Since HaCaT cells exhibit intrinsic levels of chromosomal
instability, we compared our karyotypes with the human normal karyotype (46
chromosomes). We analyzed twenty metaphases for each of the three vector control
HaCaT clones exposed to 0 or 100 nM sodium arsenite and each of the three miR-186
overexpressing HaCaT clones exposed to 0 or 100 nM sodium arsenite. Analysis of the
structural abnormalities showed that, all clones exhibited structural chromosomal
abnormalities, but statistically significant changes were not observed (Panel A,
Figure 16).
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Figure 16 : Total structural and numerical chromosomal abnormalities. A. Total structural
chromosomal abnormalities, no statistically significant changes were observed, B. Total
numerical abnormalities were plotted and statistically significant changes were observed
in cells overexpressing miR-186 and exposed or not sodium arsenite (p=0.02), C.
Number of extra marker chromosomes, statistically significant changes were observed in
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in cells overexpressing miR-186 and exposed or not sodium arsenite (p=0.04), D.
Number of double minute chromosomes, no statistically significant changes were
observed. Data are represented as the % of the mean control expression. Data are
expressed as mean +/- SD. Data are analyzed with two-way ANOVA and Tukey’s
multiple comparison post hoc test. The level of significance is established at p value ≤
0.05.
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The levels of chromosomal instability varied among clones of the same group (Panel A,
Figure 16). Specifically, we observed that one clone from the miR-186 overexpressing
cells (S1-3) exhibited higher number of total structural chromosomal abnormalities when
compared to unexposed vector control cells (Panel A,
Figure 16). Two clones (S1-1 and S1-3) from the miR-186 overexpressing cells and
exposed to arsenite (100 nM) exhibited higher number of total structural chromosomal
abnormalities when compared to unexposed vector control cells (Panel A,
Figure 16). Furthermore, analysis of the numerical abnormalities showed that, all clones
exhibited numerical chromosomal aberrations. Specifically, cells overexpressing miR186 and exposed to arsenite exhibited statistically significant reduced number of
numerical chromosomal abnormalities (p=0.02) (Panel B,
Figure 16). Additionally, cells overexpressing miR-186 and exposed to arsenite exhibited
statistically significant increase in the presence of extra marker chromosomes in all
clones (Panel C,
Figure 16). No statistically significant changes were observed in the presence of double
minute chromosomes in all clones (Panel D,
Figure 16). However, karyotypic analysis showed that one clone (S3-1) overexpressing
miR-186 showed increased number of double minute chromosomes compared to
unexposed vector control cells (Panel D,
Figure 16). Also, two clones (S1-1 and S3-1) overexpressing miR-186 and exposed to
arsenite (100 nM) showed increased number of double minute chromosomes compared
to unexposed vector control cells (Panel D,
Figure 16). Overall, HaCaT cells overexpressing miR-186 and exposed to arsenite (100
nM) showed a trend towards increased structural chromosomal abnormalities, including
the presence of double minute chromosomes. A detailed analysis of karyotypes showed
which structural abnormalities frequently occurred.
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We observed that HaCaT overexpressing miR-186 and exposed to arsenite (100
nM) more frequently exhibited structural abnormalities (Figure 16). Karyotypic analysis of
the structural abnormalities showed that, all clones exhibited structural chromosomal
aberrations as depicted in the representative karyotypes for each clone (Figure 17),
(Figure 18).
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Figure 17: Representative karyotypes of unexposed cells at 9 weeks. A. Representative
karyotype of vector control, VC1-4 clone, B. Representative karyotype of vector control,
VC3-2a clone, C. Representative karyotype of vector control, VC3-2b clone, D.
Representative karyotype of miR-186 overexpressing clone, S1-1 clone, E.
Representative karyotype of miR-186 overexpressing clone, S1-3 clone, F.
Representative karyotype of miR-186 overexpressing clone, S3-1 clone. Green arrow:
shows structural chromosomal instability (deletion) in chromosome 1p, purple arrow:
shows the presence of marker chromosomes, yellow (or orange) arrow: shows the
structural chromosomal instability (gain of unidentified chromosomal material) in
chromosome 20.
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Figure 18: Representative karyotypes of arsenic exposed cells at 9 weeks. A.
Representative karyotype of vector control, VC1-4 clone, B. Representative karyotype of
vector control, VC3-2a clone, C. Representative karyotype of vector control, VC3-2b
clone, D. Representative karyotype of miR-186 overexpressing clone, S1-1 clone, E.
Representative karyotype of miR-186 overexpressing clone, S1-3 clone, F.
Representative karyotype of miR-186 overexpressing clone, S3-1 clone. Green arrow:
shows structural chromosomal instability (deletion) in chromosome 1, blue arrow: shows
double minute chromosomes, red arrow: shows structural chromosomal instability (gain
of unidentified chromosomal material) in chromosome 11, purple arrow: shows the
presence of marker chromosomes, yellow (or orange) arrow: shows the structural
chromosomal instability (gain of unidentified chromosomal material) in chromosome 20.
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However, the miR-186 overexpressing clones and exposed to arsenite (100 nM)
exhibited some structural chromosomal abnormalities more frequently compared to
unexposed vector control cells. These abnormalities included deletion of chromosomal
material in chromosome 1p, extra chromosomal material of unknown origin in
chromosomes 11 and 20 and extra marker chromosomes (Figure 20) (Figure 21). These
observations suggest that miR-186 overexpression causes chromosomal instability
which is further exacerbated by arsenic exposure.
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MiR-186 induces structural chromosomal instability

Figure 19: Most common structural chromosomal abnormalities in vector control and
miR-186 overexpressing clones at 9 weeks. Number of the most common structural
chromosomal abnormalities for the three vector control clones (VC1-4, VC3-2a, VC3-2b)
exposed to 0 or 100 nM sodium arsenite (As) and for the three miR-186 overexpressing
clones (S1-1, S1-3, S3-1) exposed to 0 or 100 nM sodium arsenite (As) (Figure 17,
Figure 18). M indicates marker chromosomes. Green bar: shows structural chromosomal
instability (deletion) in chromosome 1p, blue bar: shows double minute chromosomes,
red arrow: shows structural chromosomal instability (gain of chromosomal material) in
chromosome 11, purple bar: shows the presence of marker chromosomes, orange bar:
shows the structural chromosomal instability (gain of chromosomal material) in
chromosome 20.
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Figure 20: MiRNA-186 induces structural chromosomal instability and this effect is even
more pronounced in arsenite (100 nM) exposed keratinocytes.
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Figure 21: Clonal variability in miR-186 induced structural chromosomal instability
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CHAPTER 4: DISCUSSION

Chronic arsenic exposure is a serious public health concern and arsenic poisoning
is the cause of many fatal diseases [65]. Arsenic is a toxic metalloid and established
carcinogen [2]. It is classified as a group I human carcinogen by the International Agency
of Research on Cancer (IARC) since 1980 [89]. The latter means that there is sufficient
evidence of carcinogenicity to humans [90]. Arsenic is also clastogenic and causes
chromosomal instability (CIN) both in vitro and in vivo [3]. CIN is a hallmark of
carcinogenesis, and is associated with poor prognosis, metastasis, and therapeutic
resistance [4]. However, the molecular mechanism by which arsenic induces CINmediated carcinogenesis is yet to be elucidated [5].
Arsenic causes several cancers, such as lung, bladder, kidney, liver and nonmelanoma skin cancer [2]. Specifically, chronic arsenic exposure is the second most
common cause of skin cancer, following sunlight-induced skin cancer [98]. Despite
evidence in humans, animal models fail to replicate these observations. The lack of an
animal model has made it difficult to determine the exact mode(s) of action underlying
arsenic-induced carcinogenicity [90]. However, human immortalized keratinocytes
(HaCaT) malignantly transformed by chronic incubation in low concentration of sodium
arsenite are a very well-established in vitro model to study arsenic-induced skin
carcinogenesis [215] [161]. Specifically, continuous exposure of HaCaT cells to
toxicologically relevant concentration [57] (100 nM) sodium arsenite for 28 weeks
induced malignant transformation [215] [161]. HaCaT cells are a spontaneously
immortalized human keratinocyte cell line with unlimited growth potential which
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maintains full epidermal differentiation capacity [214]. They are hypotetraploid with a
range of 72-88 chromosomes, and the presence of marker chromosomes (M1: t(3q4q),
M2: i[9q], and M4:[4p18q] [214]. The presence of these marker chromosomes could be
used to validate the authenticity of the cells and exclude cross-contamination with other
human cell lines [214].
MiR-186 was found to be highly upregulated in some cases of squamous cell
carcinoma induced by chronic arsenic exposure via drinking water, relative to nonmalignant hyperkeratosis [109] [183]. MiR-186 plays a crucial role in various biological
processes and may act as an oncogenic or tumor-suppressor miRNA. The likely role of
miR-186 in carcinogenesis has been reported and dysregulated miR-186 levels can
either promote or inhibit tumorigenesis [184] [150].
Upregulated miR-186 suppresses securin, which is one of its targets [185] [109].
Normally, securin binds to and inhibits a protease called separase, which, when
released, following securin degradation, cleaves cohesins that hold the sister chromatids
together, thus initiating anaphase [192]. Therefore, suppressed securin levels, because
of overexpression of miR-186, would allow anaphase progression and contribute to
aneuploidy by promoting premature chromatid separation [109]. Analysis using the
bioinformatic tool DIANA miRPath V3.0 predicted that miR-186 also targets mRNAs of
other proteins that regulate the cell cycle and are components of the spindle assembly
checkpoint (SAC) and anaphase promoting complex (APC), including: budding
uninhibited by benzimidazoles 1 (BUB1) and cell division cycle 27, (CDC27) [194].
According to the bioinformatic prediction, miR-186 targets and suppresses BUB1 and
CDC27, which play a role in the establishment of the mitotic spindle checkpoint and
proper chromosome segregation., Ectopic expression of miR-186 in HaCaT cells
induces significant increase in numerical and structural chromosomal abnormalities and
these aberrations are further increased with chronic arsenite exposure at 8 weeks of
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culture [5]. Overall, the studies described above, suggest that upregulated levels of miR186 cause chromosomal instability and exacerbate the arsenic-induced chromosomal
instability associated with skin carcinogenesis.
The focus of this study was to assess the role of miR-186 overexpression in skin
carcinogenesis and chromosomal instability in the presence or absence of chronic
arsenite exposure. We hypothesized that miR-186 overexpression contributes to
malignant transformation of HaCaT cells by induction of chromosomal instability and that
chromosomal instability and transformation will be accelerated in HaCaT cells
overexpressing miR-186 and exposed to arsenite compared to just arsenite exposed
HaCaT cells. To test this hypothesis, we had two main goals. First, we wanted to
compare timing of transformation of HaCaT cells overexpressing miR-186 and exposed
to arsenite with cells exposed to arsenite without miR-186 overexpression. Second, we
wanted to characterize the chromosomal instability in HaCaT overexpressing miR-186
with or without chronic arsenite exposure.
During tumorigenesis, EMT may increase the motility and invasiveness of cancer
cells. Malignant transformation is associated with signaling pathways promoting EMT
[330]. Specifically, during carcinogenesis cadherin switching may occur [330]. The latter
refers to a switch from expression of e-cadherin (an epithelial marker) to expression of ncadherin (a mesenchymal marker) [330]. One mechanism that most likely operates
cadherin switching is transcriptional repression of e-cadherin by transcriptional repressor
proteins (e.g. snail, slug) [330]. Also, b-catenin is a transcription factor in the Wnt
signaling pathway and is involved in the regulation of cell adhesion [332]. B-catenin is
typically more abundant in epithelial-like cells and it is reduced in mesenchymal-like
cells, such as cancer cells [332]. Claudin 1 is membrane protein involved in the
formation of tight junctions, mainly found in epithelial cells [330]. Claudin 1 regulates
transepithelial transport and plays a critical role for cell growth and differentiation [330].
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The protein levels of claudin 1 are frequently reduced in many cancers though
transcriptional repression by snail or slug, during EMT [330]. Also, zona-occludens 1
(ZO-1) is a tight junction protein that is usually located at cell-cell adhesion membrane
complexes in normal epithelial cells [333]. The cytoplasmic/nuclear delocalization of ZO1 from the tight junctions is common process of EMT and associated with tumor invasion
[332]. To elucidate the association of miR-186 overexpression with the progression to
arsenic-induced skin cancer, we tested HaCaT that overexpress miR-186 and exposed
to 0 or 100 nM sodium arsenite, for the protein expression levels of epithelial and
mesenchymal markers.
At 12 weeks, we observed no significant changes in expression of the epithelial
markers, e-cadherin, claudin 1, β-catenin, and ZO-1, and in expression of mesenchymal
markers, n-cadherin, and slug, in vector control and miR-186 overexpressing HaCaT
cells, exposed to 0 or 100 nM sodium arsenite (Figure 9). Thus, the cells did not undergo
EMT after 12 weeks. After 29 weeks under selective arsenite pressure, we observed that
the protein expression levels of the epithelial markers e-cadherin, claudin 1, β-catenin
are significantly decreased in miR-186 overexpressing and exposed to arsenite HaCaT
cells (p <0.05), compared to unexposed vector control HaCaT cells (Figure 11). At 29
weeks, we also observed no significant changes in the expression of the epithelial
marker ZO-1 in vector control HaCaT cells and miR-186 overexpressing HaCaT cells,
both in exposed and unexposed cells (Panel E, Figure 11). Hence, ZO-1 might not play
a role during the EMT process of arsenite exposed and miR-186 overexpressing cells, or
reduction of ZO-1 protein levels might be a later event of transformation process. Then,
we screened the expression levels of mesenchymal markers. We observed that the
protein expression levels of the mesenchymal proteins n-cadherin and slug, are
significantly increased in miR-186 overexpressing HaCaT cells and exposed to arsenite
(p <0.05), compared to unexposed vector control HaCaT cells (Figure 12). The
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increased levels of slug could transcriptionally repress e-cadherin and claudin 1 and
contribute to EMT. Specifically, the protein levels of slug were more decreased in miR186 overexpressing HaCaT cells and exposed to arsenite (p <0.01), compared to vector
control HaCaT cells and exposed to arsenite (Panel C, Figure 12). Analysis using
bioinformatic tools (miRbase, TargetScan) does not predict slug as a target of miR-186,
thus, miR-186 might induce slug overexpression indirectly. Thus, these data indicate that
the combination of arsenite exposure and miR-186 overexpression results cadherin
switching and EMT at 29 weeks, which is linked to invasive and metastatic phenotype.
Neoplastic transformation occurs via a series of alterations that yield a cell
population that is capable of proliferating independently of signals that restrain growth
[328]. Anchorage-independent growth is one of the hallmarks of cell transformation,
which is considered an accurate in vitro assay for detecting malignant transformation of
cells and correlates with tumorigenic potential in vivo [328]. The soft agar colony
formation assay is a common method to monitor anchorage-independent growth [328]. It
measures proliferation in a semisolid culture media after 4-6 weeks by manual counting
of colonies. HaCaT that overexpress miR-186 and exposed to 0 or 100 nM sodium
arsenite were tested for anchorage-independent growth in agar. The assay was
performed at an early time point (12 weeks) and at a late time point (29 weeks) to
assess if miR-186 overexpression accelerates the arsenic transformation process. We
observed that HaCaT overexpressing miR-186 and exposed to arsenite showed
increased growth ability in agar at 12 weeks in contrast to vector control unexposed and
exposed cells (Panel A, Figure 7). Specifically, single cells formed clusters of cells in all
miR-186 transfected clones exposed to arsenite (S1-1, S1-3, S3-1) (Panel A, Figure 7).
We also observed that all arsenite-exposed clones formed colonies in agar at 29 weeks
(Panel B, Figure 7). Specifically, the miR-186 overexpressing cells and exposed to
arsenite formed slightly bigger colonies compared with vector control and exposed to
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arsenite clones (Panel B, Figure 7). These observations suggest that miR-186
overexpression accelerates the arsenite-induced transformation process, since clusters
were formed only in this group of cells, at 12 weeks, and slightly bigger colonies were
produced at 29 weeks, compared to vector control and exposed to arsenite cells.
However, our data is not robust, since only one colony was formed per technical
replicate per clone. Repetition of this assay is crucial. In the future, we propose to design
an experiment in which we will optimize the culturing conditions. Specifically, we plan to
seed different concentrations of cells in the upper layer of agar. In addition to modifying
conditions and repeating this assay with 12 and 29 week cells, it will be important to
assay cells from intermediate times, since we want to demonstrate if accelerated
transformation occurs in miR-186 overexpressing cells and exposed to arsenite,
compared with miR-186 overexpressing cells unexposed to arsenite. Specifically, we
want to identify if there is a time when miR-186 overexpressing cells and exposed to
arsenite form colonies but miR-186 overexpressing cells unexposed to arsenite do not.
Alternatively, we could perform more in vitro assays to screen for the transformation
potential of cells. Specifically, spheroid formation assay, cell migration (i.e wound
healing) and cell invasion assay (i.e transwell assay) could produce more information
about the malignant phenotype of arsenite exposed and miR-186 overexpressing HaCaT
cells. If the results of these in vitro assays support our hypothesis, then we could
inoculate these transformed cells into tumor prone athymic nude Balb/c mice (nu/nu)
mice with subcutaneous injection into their flank, to evaluate tumorigenesis in vivo.
Cell cycle dysregulation underlies the aberrant cell proliferation that characterizes
cancer cells, and loss of cell cycle checkpoint control promotes chromosomal instability
[331]. Thus, we wanted to determine if there are any changes in the cell cycle patterns of
HaCaT cells transfected with vector control and overexpressing miR-186 exposed to 0 or
to 100 nM sodium arsenite. Thus, we performed a flow cytometry analysis at 14 weeks
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(an intermediated time point during our chronic cell culture for 29 weeks). No changes in
the cell cycle patterns were found, but we observed that all the six clones exposed to 0
or 100 nM sodium arsenite exhibited similar levels of aneuploidy (Figure 13).
Bioinformatic analysis using the DIANA miRPath V3.0, has shown that miR-186 is
predicted to target mRNAs of proteins that regulate the cell cycle and are crucial for
proper chromosome segregation, such as BUB1 and CDC27. Thus, we determined the
levels of BUB1 and CDC27 at 12 and 29 weeks. Also, we determined the protein levels
of a downstream target of BUB1, the BUB1-related protein 1 (BUBR1), which is also a
crucial component of the spindle assembly checkpoint [196]. If BUB1 is targeted by miR186, we expect decreased phosphorylation of BUBR1. BUB1 is key to proper
chromosome segregation, binding to kinetochore and delaying mitosis in response to
spindle disruption. [184]. Mutations of BUB1 have been reported in some aneuploid
tumor cell lines and primary tumors [204]. Moreover, CDC27 levels are reported to be
essential for preventing high levels of chromosomal instability [334], thus increased
levels of CDC27 expression would be consistent with the increased chromosomal
instability observed in miR-186 overexpressing clones. Also, upregulated levels of
CDC27 have been shown to promote EMT, invasion and metastasis in melanoma,
colorectal and renal cancers [335] [334]. Additionally, increased expression of BUBR1
has been associated with chromosomal instability and tumor invasion and metastasis in
gastric and breast cancers, however the underlying mechanism remains unclear [336]
[337].
At 12 weeks, we did not observe any significant difference at the levels of BUB1,
CDC27, and BUBR1, in vector control and miR-186 overexpressing HaCaT clones
(Figure 14). Thus, the bioinformatic prediction might not be accurate. In the future, a
dual-luciferase reporter assay would unravel if miR-186 binds to the 3’ untranslated
region of the BUB1 and CDC27 mRNAs. BUB1 protein levels were increased in the
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arsenite exposed clones, when compared with the unexposed clones (Panels A, B,
Figure 14). BUB1 is known to be cell cycle-dependent and a target of the anaphase
promoting complex/cyclosome as cyclin B and securin [338]. Also, arsenite exposure
increases the proportion of cells in G2 or M phase while stabilizing cyclin B in a fibroblast
model [339] and securin in a melanoma model [134]. Arsenite-induced cell cycle arrest
at G2/M is not detected in our fourteen weeks flow cytometry data (Figure 13), probably
because cells are acclimated to arsenite after long-term exposure. Hence, the arsenite
induced BUB1 expression at 9 weeks, may be due to an increase in G2 or M phase via
inhibition of the anaphase promoting complex/cyclosome [5]. At 29 weeks, BUB1 protein
levels were stable in all clones (Panels A, B, Figure 15). It is possible that cells
acclimated to arsenite exposure and overcame the arsenite-induced arrest at G2/M
phase, in which BUB1 levels are increased [338]. CDC27 protein levels were increased
in all arsenite exposed cells, when compared with the unexposed clones, at 29 weeks
(Panels, A, C, Figure 15). The latter is consistent with the knowledge that upregulated
levels of CDC27 have been shown to promote EMT, invasion and metastasis [335]
[334], since the arsenite-exposed and miR-186-overexpressing cells undergo EMT and
exhibit signs of anchorage independent growth at 29 weeks. No significant differences
for the levels of BUBR1 were found, but we observed that HaCaT overexpressing miR186 and exposed to arsenite had slightly increased levels of BUBR1, when compared to
unexposed vector control cells, at 29 weeks (Panels, A, D, Figure 15). The latter is
consistent with the literature that increased expression of BUBR1 has been associated
with chromosomal instability and tumor invasion [336] [337]. This observation could be
statistically significant if the cells are exposed to arsenite for more than 29 weeks.Also,
the phosphorylated levels of BUBR1 did not significantly change, but we observed a
slight decrease in the vector control and exposed to arsenite cells compared to
unexposed cells (Panels, A, E, Figure 15). The latter could occur because arsenite
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activates phosphatases or inhibits BUBR1 specific kinases. Overall, we observed
increased levels of CDC27 and slightly increased levels of BUBR1 in arsenite and miR186 overexpressing HaCaT cells, which could contribute to chromosomal instability and
malignant transformation. Moreover, flow cytometry indicated that all vector control and
miR-186 overexpressing clones exhibited aneuploidy (Figure 13). Thus, we wanted to
screen for specific structural and numerical chromosomal abnormalities due to arsenic
exposure, miR-186 overexpression or combination of both treatments that could drive
transformation process of HaCaT overexpressing miR-186 and exposed to arsenite.
Analysis of the structural abnormalities showed that, all clones exhibited structural
chromosomal abnormalities at 9 weeks. Specifically, we calculated the total number of
structural chromosomal abnormalities per clone and we observed that one clone from
the miR-186 overexpressing cells (S1-3) unexposed to arsenite exhibited higher number
of total structural chromosomal abnormalities when compared to unexposed vector
control cells (Panel A,
Figure 16). Also, two clones (S1-1 and S3-1) from the miR-186 overexpressing cells and
exposed to arsenite group exhibited a higher number of total structural chromosomal
abnormalities when compared to unexposed vector control cells (Panel A,
Figure 16). Thus, we observe a trend towards increased structural chromosomal
instability when there is miR-186 overexpression and concurrent arsenite exposure. We
hypothesize that the clones with the higher levels of structural abnormalities might have
higher levels of miR-186 expression. Hence, the validation of miR-186 levels with RTqPCR is crucial for us to interpret these results since the levels of miR-186 might
elucidate the correlation of miR-186 with increased structural chromosomal instability.
Moreover, karyotypic analysis showed that one clone (S3-1) overexpressing miR-186
and unexposed to arsenite showed increased number of double minute chromosomes
compared to unexposed vector control cells (Panel C,
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Figure 16). Also, two clones (S1-1 and S3-1) overexpressing miR-186 and exposed to
arsenite showed increased number of double minute chromosomes compared to
unexposed vector control cells (Panel C,
Figure 16). Thus, we observe that there is trend towards increased number of double
minutes in arsenite exposed and miR-186 overexpressing cells. Double minute
chromosomes lack regulatory elements, and they frequently harbor amplified oncogenes
[243]. These data are derived from analysis of twenty metaphases per clone and are
therefore preliminary. We intend to analyze fifty metaphases per clone in future studies.
Increasing the number of metaphases analyzed, could produce statistically significant
data by reducing the standard deviation within the technical replicates. Also fluorescent
in situ hybridization (FISH) and RNAscope could further produce information about any
oncogene amplification events that occur in double minutes of arsenite exposed and
miR-186 overexpressing keratinocytes and contribute to their malignant phenotype.
Additionally, a detailed karyotypic analysis showed which structural abnormalities
frequently occurred. The miR-186 overexpressing clones and exposed to arsenite
exhibited some structural chromosomal abnormalities more frequently compared to
unexposed vector control cells (Figure ) (Figure 20) (Figure 21). These abnormalities
included deletion of chromosomal material in chromosome 1, extra chromosomal
material of unknown origin in chromosomes 11 and 20 and extra marker chromosomes
(Figure ) (Figure 20) (Figure 21). Analysis of the genes located in those regions could
elucidate gene dosage effects that could be implicated in transformation process as well
as unravel pathways that lead to the acquisition of tumorigenic phenotype.
The gains of unidentified chromosomal material in chromosomes 11 and 20, as well
as the deletion of chromosomal material in chromosome 1, could be potential sites of
chromosomal translocations and gene fusion events (Figure 21). Gene fusions represent
an important class of somatic alterations in cancers, and it is estimated that they drive the
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development of approximately 17% of cancer cases [4]. We have started a gene fusion
analysis from RNA sequencing data obtained from miR-186 overexpressing clones
exposed to 0 or 100 nM sodium arsenite. If our ongoing analysis shows evidence of unique
gene fusion events, we propose to design primers that will flank the fusion junction in the
fused mRNA and perform genomic PCR to validate the presence of these fusions. Overall,
our karyotypic observations suggest that miR-186 overexpression causes chromosomal
instability which is further exacerbated by arsenic exposure.
The research summarized in this thesis showed that HaCaT cells overexpressing
miR-186 and exposed to arsenite had increased chromosomal instability that has been
associated with skin cancer progression, since these cells also showed evidence of
transformation in vitro.

We observed that the arsenite exposed and miR-186

overexpressing cells demonstrate hallmarks of EMT at 29 weeks and that concurrent miR186 overexpression and arsenite exposure probably accelerates the transformation
process since miR-186 overexpressing cells and exposed to arsenite exhibited signs of
anchorage independent growth at 12 weeks, and formed slightly bigger colonies at 29
weeks compared to vector control and exposed to arsenite cells. Also, arsenite exposed
and miR-186 overexpressing cells had increased levels of structural chromosomal
aberrations and CDC27 and BUBR1 protein levels, which are known to promote
chromosomal instability, invasion, and metastasis. Carcinogenesis is a multistage
process, in which cancer cells evolve in response to multiple hits. Overexpression of miR186 could be a second hit that exacerbates the effect of the first hit, which is the arsenite
exposure. Not all cells within each clone are going to transform simultaneously since the
transformation process is a stochastic event. The latter explains the karyotypic variability
that we observed (Figure 21). Cells that will acquire beneficial phenotypic traits, such as
sustained proliferative signaling or resistance to death, will clonally expand and
outcompete less fit neighboring cells [340].
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The novelty of this study is the emerging link of miRNA dysregulation and
chromosomal instability, as a suggested mechanism of arsenic-induced carcinogenesis,
which could serve miR-186 as a potential biomarker for the progression from premalignant
hyperkeratosis to metastatic squamous cell carcinoma.
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